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Abstract 
 
A major advantage of DNA vaccination is the ability to induce both humoral and 
cellular immune responses. DNA vaccines are currently used in veterinary medicine, but 
their tendency to display low immunogenicity in humans has hindered their usage, 
despite excellent tolerability and safety profiles. Various approaches have been used to 
improve the immunogenicity of DNA vaccines.  Recent human study data re-established 
the value of DNA vaccines, especially in priming high-level antigen-specific antibody 
responses.  Data suggests that innate immune responses to the DNA vaccine plasmid 
itself contribute to the immunogenicity of DNA vaccines, however the underlying 
mechanisms responsible remain unclear. In this dissertation, we investigate the role of 
innate immunity in shaping antigen-specific adaptive immune responses following DNA 
vaccination. 
The current belief is that the cytosolic DNA sensing pathways govern DNA 
vaccine immunogenicity.  To date, only the type I interferon inducing STING/TBK1 
regulatory pathway has been identified as required for DNA vaccine immunogenicity. 
Surprisingly, neither the upstream receptor nor the downstream signaling molecules in 
this pathway have been characterized.  I therefore investigated a candidate cytosolic 
DNA receptor, as well as the downstream transcription factors required for generation of 
antigen-specific immune responses.  Additionally, the effects of pro-inflammatory 
signaling on DNA vaccine immunogenicity have yet to be comprehensively studied.  
Previous studies have only provided indirect evidence for the role of inflammatory 
vsignaling in DNA vaccination.  As such, I also investigated the role of the DNA sensing 
AIM2 inflammasome in DNA vaccination. My data indicates that AIM2 is a key 
modulator in DNA vaccination via a previously unrecognized connection to type I 
interferon. Importantly, this marks the first time a DNA vaccine sensor has been 
identified. 
Of note, this dissertation represents a departure from many published works in the 
field.  Whereas previous studies have mostly utilized model antigens and only focused on 
the adaptive immune responses generated, I analyzed the effects on innate immunity as 
well. Using various innate gene knockout murine models, I quantified antigen-specific 
humoral and T cell responses, as well as serum cytokine and chemokines following 
immunization with a clinically relevant DNA vaccine.  Overall, this data provides a basis 
for understanding the mechanisms of DNA vaccination, allowing for the design of more 
effective vaccines.  
vi
Table of Contents 
 
Signature Page……………………………………………………………………….........ii 
Acknowledgements…...………………………………………………………………….iii 
Abstract……….…………………………………………………………………………..iv 
Table of Contents…………………………………………………………………………vi 
List of Figures……………….………………………………………………………........ix 
List of Abbreviations…………………………………………………………………….xii 
Chapter I: Introduction…………………………………………………………………….1 
Current Vaccine Platforms………………………………………………………...2 
Live attenuated……………………………………………………………2 
Inactivated………………………………………………………………....2 
Subunit…………………………………………………………………….3 
DNA Vaccines………………………………….………………………………....4 
Plasmid based vaccine ………………………………………………...….4 
Benefits of DNA vaccination……………………………………………...4 
Progress of DNA vaccination……………………………………………..5 
Early DNA vaccine studies……………….……...………………..5 
   Human DNA vaccine studies……………….……...……………..6 
Recent human trials……………….……...……………………….6 
Mechanism of DNA vaccine……………….……………………………...8
Innate Immune Signaling………………………………………………………12 
vii
Pattern recognition receptors ……………………………………………12 
Type I IFN and regulation by PRRs………….………………………….13 
Nucleic Acid Sensing PRRs……………………………………………...16 
IFN inducing PRRs………………………………………………16 
Cytosolic DNA receptors…………….…………………………..17 
Requirement of type I IFN in DNA vaccination …...……………21 
Pro-inflammatory PRRs……………………………….………………..22 
The inflammasome ……………………………………………..22 
AIM2 inflammasome……………………………………………23 
DNA vaccination and inflammatory signaling………………….26 
Research Objectives……………………………………………………………...26 
Preface to Chapter II……………………………………………………………………..29 
Chapter II: IRF7 mediates DNA vaccine induced adaptive immune responses. 
Introduction………………………………………………………………………30 
Results……………………………………………………………………………33 
Discussion………………………………………………………………………..51 
Preface to Chapter III…………………………………………………………………….54 
Chapter III: Identification of Aim2 as a DNA vaccine sensor. 
Introduction………………………………………………………………………55 
Results……………………………………………………………………………58 
Discussion………………………………………………………………………..79 
Preface to Chapter IV………………………………………………………………….....82 
viii
Chapter IV: The Aim2 inflammasome is required for alum adjuvanticity. 
Introduction………………………………………………………………………83 
Role of Adjuvants in Vaccination………………………………………..83 
Vaccine formulations with aluminum salt adjuvants…………….83 
Cellular mechanism for alum adjuvanticity…………………….………..84 
Antigen depot effect…………………………..………………….85 
Aluminum adjuvants and the inflammasome...………………….85 
Results…………………………………………………………………………....88 
Discussion………………………………………………………………………..98 
Chapter V: Materials and Methods……………………………………………………..100 
Chapter VI: Final Comments and Conclusions………………………………………...111 
Chapter VII: Bibliography……………………………………………………………...120
ix
List of Figures 
 
 Chapter I 
Figure 1.1: Induction of antigen-specific, adaptive immunity by DNA vaccination….....11 
Figure 1.2: Interferon-regulatory factors 3 and 7 function as a positive-feedback loop for 
regulation of type I interferon genes……………………………………………………..15 
Figure 1.3: IFN-αβ inducing, cytosolic DNA sensors. ………………………...………..20 
Figure 1.4: AIM2 detects cytosolic DNA and triggers a pro-inflammatory response..….25 
Figure 1.5:  DNA vaccine study design and immunization schedule…………………....28 
Chapter II 
Figure 2.1:  Sting is required for DNA vaccine immunogenicity..……………………....35 
Figure 2.2: DNA vaccine induced antibody responses are Sting dependent…………….36 
Figure 2.3: cGas is required for IFN-αβ production in vitro. ..…………………….…....38 
Figure 2.4: cGas deletion does not limit cytokine production. ....……………………….39 
Figure 2.5: DNA vaccine immunogenicity is cGas independent. ....…………………….40 
Figure 2.6: IFN-αβ production is delayed cGas-/- mice. …………....…………………….41 
Figure 2.7: Irf3 is required for DNA vaccine-induced IFN-αβ production in vitro………43 
Figure 2.8: Irf3 is dispensable for DNA vaccine immunogenicity…………………………44 
Figure 2.9: Irf7 is required for immune cytokine production……………………………46 
Figure 2.10: IFN-αβ production following DNA vaccination is Irf7 dependent………...47 
xFigure 2.11: Irf7 is required for generation of anti-pH1HA adaptive immune responses.49 
Chapter III 
Figure 3.1: Plasmid DNA vaccination induces the inflammasome……………………...60 
Figure 3.2: pH1HA immunization generates catalytically active caspase-1…………….61 
Figure 3.3: Aim2 is required for IL-1β production in response to DNA vaccines. …..…63 
Figure 3.4: Aim2 is required for pro-inflammatory cytokine production in response to 
DNA vaccines..……………………..................................................................................66 
Figure 3.5: Optimal DNA vaccine immunogenicity requires Aim2……………………..67 
Figure 3.6: Asc is required for DNA vaccine immunogenicity………………………….68 
Figure 3.7: Aim2-deficient mice exhibit diminished caspase-1 activation at the site of 
immunization...……………………..................................................................................70 
Figure 3.8: IL-1β and IL-18 are dispensable for DNA vaccine immunogenicity………..71 
Figure 3.9: Contribution of hematopoietic and non-hematopoietic cells to DNA vaccine 
induced immunogenicity. ...…….…..................................................................................73 
Figure 3.10: Aim2-deficiency limits IFN-αβ production at the site of injection…………76 
Figure 3.11: Aim2 is required in both hematopoietic and non-hematopoietic populations 
for IFN-αβ production at the site of injection……………………………………………77 
Figure 3.12: Asc is required for DNA vaccine induced IFN-αβ production…………….78 
Chapter IV 
Figure 4.1: Aim2 is required for IL-1β production in response to alum treatment……...89  
Figure 4.2:  TIV + alum study design and immunization schedule……………………...91 
Figure 4.3: Alum adjuvanted humoral responses require Aim2…………………………92  
xi
Figure 4.4: Contribution of hematopoietic and non-hematopoietic cells to alum 
adjuvanticity....……………………...................................................................................95 
Figure 4.5: Aim2-deficiency limits IFN-αβ production at the site of injection…………..97 
Chapter VI 
Figure 6.1: Proposed model for innate immune recognition of DNA vaccines………...119 
  
xii
List of Abbreviations 
 
AIM2   Absent in melanoma 2 
ALOH3  Aluminum hydroxide gel 
APC   Antigen-presenting cell 
ASC   Apoptosis-associated speck-like protein containing a CARD 
ATP  Adenosine 5’triphosphate 
BMDC  Bone marrow-derived dendritic cells 
BMDM  Bone marrow-derived macrophage cells 
CARD  Caspase activation and recruitment domain 
CBA   Cytometric bead array 
cGAS  Cyclic guanosine monophosphate–adenosine monophosphate synthase 
cGAMP Cyclic guanosine monophosphate–adenosine monophosphate 
CMI   Cell-mediated immunity 
CMV   cytomegalovirus 
CpG   Deoxycytidylate-phosphate-deoxyguanylate 
CTL   Cytotoxic T Lymphocyte 
DAI  DNA-dependent activator of IFN-regulatory factors 
DC   Dendritic cell 
DNA   Deoxyribonucleic acid 
ELISA  Enzyme linked immunosorbent assay 
ELISPOT  Enzyme-linked immunosorbent spot assay 
xiii
EP   Electroporation 
FACS   Fluorescence-activated cell sorting 
FBS   Fetal bovine system 
G-CSF  Granulocyte colony stimulating factor 
GM-CSF  Granulocyte macrophage colony-stimulating factor 
GTP  Guanosine 5’-triphosphate 
HIV-1   Human Immunodeficiency virus type 1 
HMGB1 high mobility group box 1 protein 
IFI16   Gamma-interferon-inducible-protein 16 
IFN-αβ  Type I Interferon 
IL   Interleukin 
IFNAR Type I interferon receptor 
IM   Intramuscular injection 
IRF   Interferon regulatory transcription factor 
KC   Keratinocyte chemoattractant 
LPS  Lipopolysaccharide 
MEF  Mouse embryonic fibroblast 
MHC   Major histocompatibility complex 
MIP-1α  Macrophage inflammatory protein 1 α 
MIP-1β  Macrophage inflammatory protein 1 β 
mRNA  Messenger ribonucleic acid 
MyD88  Myeloid differentiation primary response 88 
xiv
NaSCN  Sodium thiocyanate 
NFκB  Nuclear factor kappa B 
NK   Natural killer cell 
NLR   Nucleotide-binding oligomerization domain (NOD) like receptors 
NLRP3  NOD-like receptor 3 
OAS  2ʹ–5ʹ-oligoadenylate synthase 
PAMP  Pathogen-associated molecular patterns 
pDC  Plasmacytoid dendritic cell 
PYHIN  Pyrin and HIN domain-containing protein family 
PRR   Pattern recognition receptor 
RANTES  Regulated on activation, normal T cell expressed and secreted 
STING  Stimulator of interferon genes 
TBK1   TANK-binding kinase 1 
TIV             Trivalent Inactivated Vaccine 
TLR              Toll-like receptor 
TNF   Tumor necrosis factor 
TRIF   TIR-domain-containing adaptor-inducing interferon 
VSV   Vesicular stomatitis virus
1Chapter I 
 
1. Principles of Vaccination and Current Vaccine Classifications. 
Vaccines induce protective immune responses that prevent or control an infection.  
They represent one of the great achievements in public health. Edward Jenner’s 
demonstration of vaccination to protect humans from small pox over 200 years ago 
marked a turning point in the war against infection by a pathogen.  Today, the use of safe 
and effective vaccines to prevent infection is a fundamental aspect of modern medicine.  
While many vaccination campaigns have been successful, emerging pathogens constantly 
challenge scientists to develop new vaccination technologies for improved safety and 
efficacy.   
The goals of each vaccine are dependent on the immune response required for 
protection against a given pathogen.  Previously, the effectiveness of a vaccine was 
predominantly evaluated by its ability to induce protective antibodies, but recent studies 
suggest that the induction of T cell responses, especially T helper 1 (Th1) and CD8+ T 
cells, may be desirable for protection against intracellular pathogens [1-3].  Ideally, the 
most efficient vaccines will stimulate both cellular and humoral immune responses [4].  
Therefore, many investigators are striving to identify new vaccine formulations capable 
of generating balanced immunity. 
 While the principles and effectiveness of vaccination are firmly established, many 
of the underlying immunological mechanisms remain unclear.  Intensified research in the 
field of vaccine immunology suggests that triggering of the innate immune system 
enhances the adaptive immune response generated by vaccination [5-7].  This appears to 
2be a common trait of many efficient vaccines. However, as the study of innate immunity 
is still in its nascent stages, the signals required for conditioning adaptive immune 
responses are not completely understood.  Increased insight into the effect of innate 
immune signals on the adaptive response will provide a basis for the design of future 
vaccines.  
1.1 Live Attenuated Vaccines. 
Several types of vaccines are currently licensed for clinical use.  The first, and 
historically most protective, are live-attenuated vaccines. Live-attenuated vaccines are 
derived from disease causing viruses or bacteria that have been weakened, usually by 
repeated culture passage.  Live-attenuated vaccines replicate within the host, resulting in 
low levels of infection without disease.  They elicit strong cellular and antibody 
responses, as well as sustained immunity after one or two doses. As they are living, 
pathogenic organisms, live-attenuated vaccines do have some inherent safety concerns.  
Immunocompromised individuals may not be indicated for live attenuated vaccines.  To 
certain high-risk pathogens, such as human immunodeficiency virus 1 (HIV-1), it is 
difficult to produce a live attenuated vaccine with a sufficient safety margin.  
Furthermore, although extremely rare, the possibility for reversion to a pathogenic form 
exists [8].  As such, although live-attenuated vaccines have been extremely successful in 
the past, they can present challenges for use in future vaccine development. 
1.2 Killed or Inactivated Vaccines. 
A second type of vaccine encompasses killed or inactivated vaccines (often toxoid 
vaccines against several bacterial pathogens are included in this group as well).  These 
vaccines represent an alternative to live-attenuated vaccines, as they are not live and 
3cannot replicate. Typically, inactivation is accomplished through either physical methods 
such as heating or ultraviolet light treatment, or chemical means such as formaldehyde or 
formalin.  While inactivated vaccines are considered safer than live-attenuated vaccines, 
they are generally less immunogenic, often requiring multiple doses for inducing 
protective immunity.  Inactivated vaccines tend to induce only humoral responses, with 
limited ability to elicit high-level cellular immunity.  Antibody titers elicited by 
inactivated vaccines often diminish with time, requiring periodic boosting doses in future 
years.  Additionally, inactivation may also have the unwanted side effect of altering the 
antigen’s structure, thereby inhibiting the development of antibodies against the critical 
conformational antigens.  
1.3 Subunit Vaccines. 
A third type of vaccine are the subunit vaccines, which like inactivated vaccines 
do not contain live components, but instead contain only the antigenic parts of the 
pathogen.  Subunit vaccines can be further categorized depending on the nature of the 
antigen i.e. recombinant protein, polysaccharide, or conjugate vaccine wherein the sugar 
antigens are attached to a carrier protein. As with inactivated vaccines, subunit vaccines 
generally induce protection for a much shorter duration than live-attenuated vaccines and 
require a series of vaccinations to even establish the initial protective immunity.  
Recombinant subunit protein vaccines often require the addition of an adjuvant as part of 
the formulation to increase immunogenicity. Also, subunit vaccines have not proven 
especially effective in generating strong CD8+ T cell responses. 
4The conventional vaccine approaches described above have proven effective in 
preventing disease against a range of pathogens.  However, they have had only varying 
degrees of success against such major infections in the world as malaria and HIV.  In this 
regard, subunit HIV vaccines alone have failed to protect in phase III efficacy trials [9, 
10] and the concern about the safety and efficacy of live-attenuated and inactivated 
vaccines has prevented their use.  These factors have illustrated the need for additional 
vaccine technology, preferably one that marries the immunogenicity of live attenuated 
vaccines with the safety of subunit/inactivated vaccines.  DNA vaccines share these 
characteristics, and represent a novel vaccine strategy for inducing protective immune 
responses for the reasons outlined below. 
2. DNA Vaccination. 
2.1 DNA Vaccine Plasmid. 
DNA immunization refers to the induction of an immune response to a protein 
antigen expressed in vivo following the introduction of plasmid DNA encoding the 
polypeptide sequence of candidate antigens [11].  The encoded antigen is expressed 
under a strong promoter; the most common choice being the human cytomegalovirus 
(CMV) immediate early promoter, as it yields high levels of transgene expression [12].  
Inclusion of transcriptional enhancers such as Intron A enhances the rate of 
polyadenylation and nuclear transport of messenger RNA (mRNA) [13]. The vaccine 
plasmids are generally produced in bacterial culture, purified, and then used to inoculate 
the host. 
2.2 Benefits of DNA Vaccine Platform. 
DNA vaccination provides several advantages over other traditional vaccination 
5strategies.  DNA vaccines represent a safe, non-live vaccine approach to inducing 
immunity.  Importantly, DNA vaccines are capable of eliciting both antigen specific 
antibodies [14] and cytotoxic T lymphocyte responses (CTL) [15], something that 
remains elusive in most non-live vaccines.  The antigen of interest delivered by DNA 
vaccination is produced endogenously and presented to the immune system without 
concern of safety, a common concern with live-attenuated vaccines.   
In vivo production of antigen allows for presentation by both class I and class II 
major histocompatibility complex (MHC) molecules.  As a result, both CD4+ and CD8+ T 
cell responses are generated.  The generation of T helper populations is critical for the 
induction of high quality antibody responses via the induction of antigen-specific B cell 
responses.  Furthermore, the relative ease of DNA vaccine design and production allows 
for the quick and efficient development of immunogens via recombinant DNA 
technology.  DNA vaccines are also stable and can be used with multiple DNA vaccines.  
2.3 Progress of DNA vaccination. 
The concept of DNA vaccination arose in the early 1990s when Wolff et al. 
showed that intramuscular (IM) administration of naked DNA induced plasmid-encoded 
reporter genes in muscle cells [16].  The discovery that DNA immunization induces 
adaptive immune responses in small animals dramatically shifted the vaccine paradigm.  
One of the first demonstrations of DNA vaccine immunogenicity centered on mice 
immunized with DNA encoding the influenza A nucleoprotein (NP) [11].  Immunized 
mice developed NP-specific antibodies and CTLs, suggesting successful antigen 
presentation to both MHC class I and II molecules.  Immunized mice were protected 
against viral challenge and demonstrated accelerated viral clearance of both homologous 
6and heterologous viral strains [11].  Restimulation of CTL populations allowed for target 
cell lysing, proving that DNA vaccination could generate antigen-specific memory 
responses.  These results were shown to be reproducible in a variety of animal models 
against a wide range of pathogens [17-19]. 
The success of small animal studies led to several human clinical trials.  However, 
the protective immunity observed in small animals and non-human primates was not 
observed in human studies when DNA vaccines were used alone and delivered by 
conventional needle injection.  Although DNA vaccines were safe and well tolerated, 
they proved to be poorly immunogenic.  Antibody titers were either low or nonexistent, 
and CTL responses were inconsistent [20].  Also, no changes in viral load or lymphocyte 
counts were observed.  Some success was obtained with highly immunogenic antigens, 
especially when a gene gun approach was used.  For example, human subjects 
immunized with a DNA vaccine expressing hemagglutinin antigen of influenza H1 
developed measurable anti-HA antibodies by gene gun inoculation, establishing that 
DNA vaccination can induce immune responses in human subjects [21, 22]. The reasons 
for lower immunogenicity in humans remain unclear, but several advances in current 
trials have shown that DNA vaccination can be an attractive platform either alone or as 
part of a prime-boost platform. 
In an effort to increase immunogenicity, several improvements were made to the 
vaccine delivery method.  An important approach to overcoming low immunogenicity is 
to increase the amount of DNA plasmid delivered to cells by external physical force.  The 
traditional route of DNA immunization is IM injection of DNA diluted in saline, which 
has the benefit of requiring no special delivery system and can be delivered without 
7specific tools or instruments.  However, standard IM injection is associated with low 
transfection efficiency.  Therefore, many immunization regimens utilize intramuscular 
electroporation to optimize vaccine uptake by cells at the site of injection.  
Electroporation has long been known to increase transfection efficiency in vitro, but 
evidence suggests it also has positive effects in vivo. Injection of naked plasmid followed 
by application of an electrical pulse induces transient enhancement of cell permeability, 
allowing DNA to traverse the lipid bilayer down the concentration gradient [23, 24].  It is 
difficult to quantify directly the enhancement of plasmid delivery, but indirect 
measurements have shown both increased gene expression and immune responses 
following administration of an electrical pulse [25-29].  Electroporation also has the 
added advantage of enhancing the influx of antigen presenting cells (APCs) to the site of 
injection, promoting antigen presentation [30].  
Another popular technique involves propelling DNA plasmid-coated gold beads 
into the skin using a gene gun.  The Helios gene gun (Bio-Rad Laboratories, Irvine, CA) 
uses high-pressure, helium gas-powered particle bombardment to directly transfect target 
cells or tissues.  Studies have demonstrated the ability of gene gun immunization to 
induce protective immunity in both mice [31] and humans [32, 33].  Several differences 
exist between IM and gene gun immunization.  As the gene gun delivery system is more 
efficient in delivering vaccine into cells, significantly less plasmid DNA is required for 
generating protective immunity by gene gun immunization in mice [34, 35]. It is a 
potentially important issue that only a small amount of DNA can be coated onto the gold 
beads.  However, the main reason preventing wider use of gene gun technology is the 
limited access to this technology.   
8Perhaps the major novel immunization method to have emerged from early 
human trials is the heterologous DNA prime-protein boost vaccine regimen.  The 
heterologous prime-boost platform consists of an initial DNA-priming immunization 
followed by a boosting immunization of recombinant protein [36, 37]. DNA prime-
protein boost immunization has been extensively examined in the context of multiple 
pathogens. Both preclinical [38-42] and human HIV studies [17] have shown promise in 
generating protective adaptive responses.  Likewise, influenza A [43-46] and malaria [15, 
47-49] trials have resulted in generation of protective immunity.  Not only did these 
studies prove that DNA vaccination is feasible in humans, but they also demonstrated that 
DNA priming dramatically alters the adaptive response; with subjects receiving the DNA 
prime generating significantly increased CTL and humoral responses when compared to 
those receiving two doses of protein alone [43, 45].  Moreover, DNA immunization 
appears to improve the breadth and length of the adaptive immune response.  In 
particular, the memory B cell response generated by DNA immunization is significantly 
enhanced, with sustained titers [35, 50] and improved B cell development within the 
germinal center, possibly a result of increased follicular helper T cell generation [51]. 
These results suggest that DNA vaccination provides an intrinsic adjuvant effect that 
alters the adaptive immune response through processes that remain unclear.  One possible 
explanation for this outcome is the triggering of innate immune systems by DNA vaccine 
plasmids, resulting in signals that guide both the humoral and CTL responses. 
2.4 Mechanism of DNA Vaccination. 
The mechanism by which DNA vaccines induce adaptive immune responses has 
been well studied. The gene of interest is delivered either intradermally, subcutaneiously, 
9or directly into muscle by one of the previously described delivery methods.  It is 
believed that local myocytes and keratinocytes, including resident APC populations, are 
directly transfected by DNA vaccines via phago- or pinocytosis [52].  Upon entering the 
host nucleus, encoded genes are transcribed and translated by host cellular machinery 
[53], resulting in expression of antigenic peptides.  The host-synthesized antigens mimic 
infection by either being presented as endogenous antigen on MHC class I molecules, or 
the antigen is shed exogenously, allowing for presentation on MHC class II molecules.  
Furthermore, the engulfment of apoptotic, transfected cells by APCs also allows for the 
cross-presentation of exogenous antigen. Antigen-loaded APCs travel to the draining 
lymph nodes where they present antigenic peptide–MHC complexes in combination with 
signalling by costimulatory molecules to naive T cells [52]. This interaction provides the 
necessary secondary signals to initiate an immune response, driving T cell activation, or 
alternatively, to activate B cell and antibody production cascades (Figure 1.1). In this 
way, both humoral and cellular immune responses are generated.  
The in vivo production of antigen is a key component in generating protective 
immunity following DNA vaccination.  As antigen is produced directly by host cells, 
antigenic proteins undergo well-regulated translation processes, allowing for preservation 
of native protein confirmation, as well as normal post-translational modifications, such as 
glycosylation.  This allows for accurate mimicking of live-attenuated vaccines without 
the inherent safety risks [54, 55]. 
In addition to the in vivo production of antigen, it is hypothesized that the use of 
plasmid DNA itself plays a significant role in DNA vaccine immunogenicity.  Plasmid 
DNA contains unmethylated deoxycytidylate-phosphate-deoxyguanylate (CpG) motifs, 
10
which are known to prime APC populations, increasing their ability to stimulate cognate 
antigen specific CD4+ and CD8+ T cells.  Furthermore, recent evidence has demonstrated 
that cytosolic DNA itself is a potent trigger of innate immune responses through a variety 
of pathways [56-58].  How each of these factors impact the immune response induced by 
DNA immunization will be addressed in the following sections. 
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Figure 1.1: Induction of antigen-specific, adaptive immunity by DNA vaccination. 
Optimized gene sequences are inserted into a plasmid backbone and then delivered to the 
host via one of several delivery methods.  Vaccine plasmid enters the nucleus of host 
myocytes and antigen presenting cells by using host cellular machinery.  The plasmid 
components are transcribed and protein is produced.  The cell provides endogenous post-
translational modifications to antigens, producing native protein conformations.  Vaccine-derived 
endogenous peptides are presented on MHC class I molecules.  Engulfment of apoptotic or 
necrotic cells by APCs also allows for cross-presentation of cell-associated exogenous antigens. 
Secreted antigen is captured and processed by antigen presenting cells, and presented on MHC 
class II.  Antigen experienced APCs migrate to the draining lymph node to stimulate CD4+ and 
CD8+ T cell populations.  In addition, shed antigen can be captured by antigen-specific high 
affinity immunoglobulins on the B cell surface for presentation to CD4+ T cells, driving B cell 
responses. 
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3. Innate Immune Signaling. 
3.1 Pattern Recognition Receptors. 
The immune system can be divided into two broad categories: the innate and the 
adaptive immune responses.  In contrast to the adaptive immune system, which develops 
a broad repertoire of antigen-specific receptors, the innate immune system represents the 
first line of defense against invading microbes. The innate system’s primary role is to 
initiate an immediate response designed to contain infection until adaptive responses can 
clear the pathogen.  It responds to a large array of pathogens via a limited repertoire of 
germline-encoded receptors known as pattern-recognition receptors (PRRs) that tend to 
function at the APC level.  
PRRs primarily recognize three types of immune triggers.  The first trigger types 
are pathogen-associated molecular patterns (PAMPs).  Microbial PAMPs include lipids 
such as lipopolysaccharide (LPS), bacterial flagellin, peptidoglycans, and nucleic acid 
variants normally associated with viruses or bacteria.  Microbial nucleic acids, in 
particular, are extremely effective in stimulating PRRs.  The strict specificity of PRRs 
allows for the differentiation of self nucleic acids from microbial nucleic acids (double-
stranded RNA or unmethylated CpG motifs) based on differences in their structure, 
molecular modifications, or localization [59-61].  The second type of trigger involves the 
detection of endogenous molecules released upon necrotic or pyroptotic cell death.  
These so-called danger-associated molecular patterns (DAMPs) include many nuclear or 
cytosolic proteins, that upon exposure to the extracellular space, move from a reducing to 
oxidizing milieu, resulting in their denaturation [62].  Mislocalized self-nucleic acids also 
function as DAMPs [59, 63].  For example, RNA stimulates PRRs should it be present in 
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the extracellular space.  Similarly, extranuclear DNA is an exceedingly powerful DAMP 
capable of activating a variety of PRRs.  The final signal type, alarmins, are inhibitory 
signals expressed on healthy cells, but not found on infected cells or non-self pathogens 
[64].  In general, alarmins are not thought to play a significant role in vaccination. 
3.2. Type I IFN and Regulation by PRRs. 
3.2.1 Role of Type I IFN in Immune Responses. 
Type I interferons (IFN-αβ) are the principal cytokines induced during viral and 
bacterial infection, and represent a vital component of the immune response.  IFN-αβ 
induces resistance to viral replication and directly activates natural killer (NK) cells.  
Evidence has also shown that IFN-αβ production by natural interferon-producing cells 
promotes APC maturation [65, 66].  Notably, the effect of IFN-αβ on antigen 
presentation is multi-faceted.  IFN-αβ secreted by antigen-experienced APCs stimulates 
bystander APCs, resulting in increased MHC presentation and up-regulation of co-
stimulatory molecules, which drive the T cell, and subsequent B cell, response [65, 66].  
IFN-αβ also amplifies the sensitivity of the B cell receptor, boosting the ability of naïve 
B cells to produce antibodies upon antigen recognition [67].  IFN-αβ receptor knockout 
(Ifnar-/-) mice exhibit enhanced susceptibility to viral infection [68, 69].  The broad 
stimulatory effect of IFN-αβ on the immune system illustrates its importance not only in 
pathogen immunity studies, but also vaccination as well [70, 71]. 
3.2.2. Interferon Regulatory Factors. 
IFN-αβ production is transcriptionally regulated by the interferon regulatory 
factor (IRF) family of proteins.  The IRF family contains 9 members (IRF1 to IRF9) and 
modulates innate and adaptive immune responses as well as immune cell development.  
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Perhaps the best-characterized IRFs are IRF3 and IRF7.  IRF3 and IRF7 share significant 
sequence homology, and are the central IRFs regulating type I IFN production during 
viral infection.  The triggering of certain PRRs results in IRF3 phosphorylation, which 
alleviates the auto-inhibitory domain of IRF3, releasing its transactivation domain, and 
permitting IRF3 dimerization and nuclear translocation.  IRF7 undergoes a similar 
procedure, homodimerizing with itself for IFN-α production, or forming heterodimers 
with IRF3 leading to IFN-β transcription (Figure 1.2). 
IRF3 and 7 are crucial components in the anti-viral response generated by PRR 
activation [72].  The induction of IFN-αβ in most cell types differs due to the varying 
endogenous expression levels of IRF3 and IRF7.  IRF3 expression is constitutively high 
in most cells, thus IFN-β is strongly induced early following infection.  Contrarily, IRF7 
remains at low levels in resting cells.  The initial burst of IFN-β triggers type I IFN 
signaling through the IFN-αβ receptor to induce IRF7 expression via a positive feedback 
loop, which then acts on type I IFN genes for the production of high levels of IFN-α.  
There are many upstream regulators capable of inducing IRF3 and IRF7 activation, some 
of which will be described in the following sections. 
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Figure 1.2: Interferon-regulatory factors 3 and 7 function as a positive-feedback 
loop for regulation of type I interferon genes.  
Following detection of cytosolic DNA by one or multiple sensors, interferon regulatory 
factor 3 (IRF3) and IRF7 are phosphorylated on specific serine residues, resulting in the 
homodimerization or heterodimerization of IRF3 and IRF7. IRF dimers then translocate 
to the nucleus and induce small amounts of IFN-αβ. IRF7 is required for the induction of 
type I IFN genes. IRF3 also contributes to the induction of type I IFN genes (albeit to a 
lesser extent).  In the late stages of IFN-αβ production, secreted IFNs bind and activate 
the type I IFN receptor in an autocrine or paracrine manner, leading to the induction and 
transcription of the IRF7 gene. Activation of newly synthesized IRF7, leads to the 
expression of large amounts of I IFN-αβ and many of the IFN-αβ  stimulated proteins, 
further propagating the positive feed back loop.  
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3.3 Nucleic Acid Sensing PRRs. 
3.3.1 IFN Inducing PRRs. 
3.3.1.1 Toll Like Receptors. 
Toll-like Receptors (TLRs) are the most thoroughly studied PRRs.  The Toll 
protein was initially identified in Drosophila as being necessary for dorsal-ventral 
patterning, but subsequent investigation established its importance in fly immunity.  The 
TLRs, so named because of their homology to Drosophila Toll, play a similar role in 
mammalian immunity.  TLRs detect a diverse array of PAMPs in the extracellular 
environment.  Plasma membrane anchored TLRs typically detect hydrophobic lipids and 
proteins, while the endosomal receptors detect nucleic acids.  13 TLRs have been 
identified in mice, but only 10 have been identified in humans.  TLRs 1-9 are common in 
both organisms.  TLR1, TLR2, TLR4, TLR5 and TLR6 are found on the surface of the 
plasma membrane, while TLR3, TLR7, TLR8, and TLR9 are located within the 
endosome.  
TLRs are potent producers of both IFN-αβ and pro-inflammatory signals.  Upon 
ligand binding, they initiate a variety of immune signaling cascades, resulting in the 
activation of nuclear factor kappa b (NFκB) and IRF 1, 3, 5, and 7 [73].  The endosomal 
TLRs 3, 7, 8, and 9 are powerful receptors for nucleic acids, and therefore, a great deal of 
light has been shed on their ability to induce type I IFN in response to infection.  While 
all four receptors are stimulated by nucleic acids, they each require specific ligands.  Both 
TLR7 and 8 recognize long, single-stranded RNAs, but each leads to a distinct cytokine 
profile [74].  In contrast to TLR7 and 8, TLR3 is activated by dsRNA, a common viral 
PAMP [75].  Finally, TLR9 recognizes the unmethylated CpG motifs in viral and 
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bacterial DNA [76]. 
The TLR response evoked by PAMPs and DAMPs depends on a mixture of 
factors.  Most notably, TLR expression varies amongst innate cell types.  For instance, 
human macrophages express high levels of TLR2 and TLR4 while plasmacytoid 
dendritic cells (pDCs) mainly express TLR7 and TLR9 [73]. Furthermore, variations in 
TLR expression are seen between mammalian species.  TLR9 expression is limited to a 
few cell types in humans, but widely distributed in mice [77].  The expression of certain 
downstream signaling molecules also fluctuates between innate cell types.  pDCs are 
unique in that they constitutively express the transcription factor IRF7, allowing for quick 
production of type I IFN in response to viral infection while other cell types such as 
conventional macrophages may respond in a delayed manner [78, 79].  Thus, the 
response to identical ligands may differ between cell types both in the nature of effector 
molecules produced and the kinetics of the response. 
3.3.1.2 Cytosolic DNA Receptors. 
TLRs detect viral PAMPs in the extracellular space, but a unique subset of innate 
sensors patrols the intracellular spaces as well (Figure 1.3).  These sensors were 
discovered within the last decade during investigations of TLR-deficiency on viral 
infection and have yielded several classes of DNA sensors required for clearance of 
cytosolic replicating viruses.  
3.3.1.2.1 STING/TBK1/IFN Pathway. 
 It has been known for many years that pathogen-derived DNA stimulates IFN-αβ 
in TLR-deficient fibroblasts.  Medzhitov et al. demonstrated that Tlr9-/- mouse embryonic 
fibroblasts (MEFs) produce large amounts of IFN-αβ when transfected with either B-
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form dsDNA or genomic DNA isolated from bacteria, viruses, or mammals [58].  Further 
work has identified the key components of this pathway, namely the non-canonical IκB 
kinase, TANK-binding kinase 1 (TBK1).  Independent of TLR signaling, TBK1 directly 
phosphorylates IRF3 in response to intracellular, cytosolic DNA [56-58].  TBK1-
deficient MEFs do not produce cytokines in response to B-form DNA treatment, 
establishing its role in pathogen infection.  Another important molecule is the 
endoplasmic reticulum (ER) adaptor stimulator of interferon genes (STING) [80-82].  In 
unstimulated cells, STING localizes to the ER, but traffics to perinuclear vesicles upon 
cytosolic DNA detection [80].  STING appears to interact directly with TBK1 to induce 
IRF3 phosphorylation [83].  Additionally, Sting-/- mice are highly susceptible to Herpes 
simplex virus 1 (HSV-1) and Listeria monocytogenes infection due to impaired 
production of IFN-αβ [81].  While the requirement for STING in IFN-αβ signaling in 
response to cytosolic DNA is well known, the upstream regulators of STING activation 
are still being identified. 
3.3.1.2.2 Cytosolic STING Dependent DNA Receptors. 
With the identification of STING and TBK1, the list of upstream cytosolic DNA 
sensors has grown considerably.  The first DNA sensor identified was the DNA-
dependent activator of IFN-regulatory factors (DAI, also known as DLM-1 or ZBP1).  
DAI binds both the left-handed, Z form DNA as well as the more naturally relevant B 
form DNA via two N-terminus Z-DNA binding domains [84].  Type I IFN production by 
fibroblasts in response to HCMV, HSV-1, and Listeria monocytogenes is DAI dependent.  
However, DAI-/- mice respond normally to viral dsDNA challenge, suggesting that DAI is 
cell type specific and subject to redundancy. 
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The ubiquitously expressed nucleotidyltransferase cyclic GMP-AMP synthase 
(cGAS) was recently identified as another DNA sensor upstream of STING/TBK1/IRF3 
[85-87].  cGAS synthesizes cyclic GMP-AMP (cGAMP) from ATP and GTP upon 
recognition of dsDNA.  cGAMP functions as a ligand for STING activation, leading to 
high levels of IFN-αβ expression. 
Crystal structure analysis of cGAS has provided key insights into its mechanism 
of function.  cGAS binds to DNA through electrostatic and hydrogen bonding 
interactions between the positively charged cGAS surface residues and the sugar-
phosphate backbone of DNA.  Conformational changes in the cGAS catalytic pocket 
have confirmed its role as a DNA receptor and a dinucleotide cyclase. Moreover, RNA 
binding does not result in sufficient widening of the catalytic pocket, suggesting that 
cGAS is specific for DNA [88-90]. 
The immunological significance of cGAS has been characterized in several 
studies.  cGas-/- fibroblasts and bone marrow-derived macrophages (BMDM) failed to 
produce IFN-β in response to bacterial DNA or DNA viruses, but responded normally to 
RNA viruses [86, 91].  Surprisingly, studies in both conventional and plasmacytoid DCs 
demonstrated that cGAS is the dominant DNA sensor in these cells as well [86].  In vivo 
studies utilizing HSV-1 revealed significant decreases in serum IFN-αβ levels in cGas-/- 
mice when compared to cGas+/+ mice [86]. Importantly, the presence of cGas reduced 
DNA virus lethality. While all cGas-/- mice succumbed to infection, 40% and 70% of 
cGas+/+ mice recovered following HSV-1 and Vaccinia virus infections, respectively [86, 
91].  Such data demonstrates that cGAS is a general cytosolic DNA sensor.  
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Figure 1.3: IFN-αβ inducing, cytosolic DNA sensors. 
A) The presence of cytosolic DNA triggers innate immune responses through several 
possible pattern-recognition systems. Activation of cytosoli PRRs results in STING 
activation and the recruitment of TBK1.  TBK1 phosphorylates and activates IRF3. IRF3 
subsequently dimerizes and translocates into the nucleus to up-regulate the expression of 
IRF7, leading to the production of type I IFN and other cytokines.  B) Cytosolic DNA 
activates cGAS to synthesize 2’ 3’ - cGAMP from ATP and GTP.  cGAMP, as a high 
affinity ligand for STING, binds and activates STING through a series of structural 
changes. STING activation then drives type I IFN production through the TBK1 pathway 
as described in part A. 
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3.3.1.3 Requirement for Type I IFN in DNA Vaccination. 
Tudor et al. were the first to report the requirement for IFN-αβ in DNA vaccine 
immunogenicity [92].  Mice lacking the IFN-αβ receptor (Ifnar-/-) had impaired 
production of antigen-specific antibodies and CD8+ T cells in response to DNA 
immunization.  Several innate sensing pathways generate IFN-αβ, but their requirement 
for DNA vaccination remains unknown.  For example, it was previously believed that the 
nucleic acid-sensing TLRs 3, 7, and 9 would be essential in generation of adaptive 
immune populations.  TLR9 in particular was thought to regulate DNA vaccine 
immunogenicity due to the expression of unmethylated CpG motifs within the plasmid 
backbone.  Plasmid-induced cytokine production was completely TLR9-dependent in 
vitro. Yet, while TLR9 stimulation can prime APCs, deletion does not dramatically affect 
the T and B cell response in vivo.  In fact, TLR-deficient mice mount a comparable 
immune response to wild-type mice [93, 94].  Therefore, the currently characterized 
extracellular nucleic acid sensing pathways fail to explain the immunogenicity of DNA 
vaccination. 
Ishii et al. established that TBK1 is essential for DNA vaccine immunogenicity 
[58, 95].  Tbk1-/- mice lack antigen-specific CD8+ T and B cell responses, consistent with 
Ifnar-/- mice, proving the necessity of both factors in immunization [95].  More recently, 
Ishikawa et al. showed that STING is also critical DNA for vaccine immunogenicity [80, 
81], further implying that cytoplasmic DNA receptors play a more prominent role than 
the endosomal TLRs in mediating the effect of DNA vaccines.  In an attempt to identify 
the upstream sensor for STING/TBK1 activation, Ishii et al. characterized the necessity 
of DAI in DNA vaccination.  In accordance with infection data, DAI deletion did not 
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limit vaccine immunogenicity [95], which is most likely attributable to its limited cellular 
expression. The role of cGAS in DNA vaccine immunogenicity has yet to be addressed. 
3.3.2 Pro-inflammatory PRRs. 
3.3.2.1 The Inflammasome. 
Cytosolic DNA triggers not only the transcriptional induction of type I IFN, but 
also the maturation of pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-
18 (IL-18) from their inactive forms.  IL-1β and IL-18 are transcriptionally regulated, 
requiring an initial microbial stimulus through PRRs for production of both cytokines in 
their immature pro-forms [96].  Maturation of pro-IL-1β and pro-IL-18 is regulated by 
the cysteine protease caspase-1, which in turn is present as an inactive zymogen.  The 
inflammasome complex controls the activity of caspase-1 by initiating self-cleavage into 
its active form via the apoptosis-associated speck-like protein containing a CARD (ASC) 
protein. 
Inflammatory signaling is required for most pathogen infections.  IL-1β is 
involved in immune cell recruitment and trafficking, T-lymphocyte activation, and 
induction of fever.  IL-18 boosts the cytolytic activity and IFN-γ production of NK cells 
[97].  It also increases neutrophil recruitment and activation.  Perhaps most importantly 
for vaccination, IL-18 in the appropriate cytokine milieu directs CD4+ T cells towards 
either a Th1 or Th2 humoral response [98-100].  Mice lacking either cytokine have shown 
a clear susceptibility to viral infection, signifying that both cytokines are required for 
optimal anti-viral responses [101, 102]. 
The final aspect of inflammasome activation is an inflammatory form of cell 
death known as pyroptosis [103].  Cell death is an exceedingly effective method for 
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limiting intracellular infection by eliminating the host cell, thereby preventing spread of 
infection.  A range of microbial and viral infections, as well as non-infectious host 
factors, can initiate pyroptosis [104].  Pyroptotic cell death is morphologically and 
mechanistically distinct from apoptotic and necrotic cell death.  Pyroptosis is caspase-1 
dependent, but unlike apoptosis, caspase-3, 6, and 8 independent and entails the rupturing 
of the plasma membrane via caspase-1 dependent ion channels, allowing for osmotic cell 
lysis.  Pyroptotic lysis releases pro-inflammatory intracellular contents (DAMPs) into the 
extracellular milieu [105].  Similar to apoptosis, pyroptotic cleavage and liberation of 
nuclear DNA occurs [105-107].  Bystander cells detect the released intracellular, pro-
inflammatory DAMPs, further propagating immune signals via multiple PRRs. 
3.3.2.2 AIM2 Inflammasome. 
The interferon inducible inflammasome AIM2 (absent in melanoma 2) is known 
to detect cytosolic DNA. AIM2 functions as a dimer to directly bind the sugar phosphate 
backbone of cytosolic DNA via a HIN200 domain independent of nucleotide sequence 
[108-113].  Instead dsDNA recognition by AIM2 is dependent on DNA length as 
fragments less than 80 base pairs are poor triggers of the AIM2 inflammasome [108].  
Like all inflammasome receptors, AIM2 contains a pyrin domain that dimerizes with the 
pyrin domain of ASC, allowing for the recruitment and activation of caspase-1.  Prior to 
dsDNA binding, AIM2 remains in an auto-inhibited state via an intramolecular 
association between its HIN200 and pyrin domains. 
AIM2 is an integral cog in the innate immune response to certain DNA viruses 
and cytosolic bacteria.  It is required for pro-IL-1β/pro-IL-18 cleavage in response to 
Vaccinia virus and murine cytomegalovirus, as well as Francisella tularensis.  Aim2-/- 
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mice fail to activate caspase-1 or generate mature IL-1β, resulting in poor NK cell 
activation and high pathogen loads [114-117].  Surprisingly however, AIM2 is not 
required for all DNA viruses, as HSV-1 escapes detection, despite being a potent 
activator of IL-1β.  Evidence also exists for AIM2 playing a role in autoimmunity by 
initiating an inflammatory response to self-DNA [118-120].  Yet, it is not entirely clear as 
to what cell lineages require AIM2 for control of infection.  Current data suggests that 
AIM2 is necessary in hematopoietic populations, but its role in non-hematopoietic cells 
remains uncharacterized. 
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Figure 1.4: AIM2 detects cytosolic DNA and triggers a pro-inflammatory response. 
Cytosolic DNA from invading viruses and bacteria engages and activates absent in 
melanoma 2 (AIM2), resulting in binding to the adapter molecule ASC. ASC mediates 
caspase-1-dependent pro-interleukin-1β (pro-IL-1β)/pro-IL-18 cleavage and secretion 
into their bioactive forms. IL-1β and IL-18 are significant mediators of inflammatory 
responses to infection. Caspase-1 activation also results in pyroptotic cell death, yielding 
the release of pro-inflammatory DAMPs and PAMPs, thereby propagating the immune 
response to bystander cells. 
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3.3.2.3 The Inflammasome and DNA Vaccination. 
Pro-inflammatory signaling is necessary for combating the vast majority of 
pathogen infections; yet, its role in vaccination has been largely unexplored.  As such, the 
requirement for IL-1β and IL-18 in DNA vaccination has yet to be definitively addressed.  
The current belief is that inflammasome signaling is dispensable for DNA vaccine 
immunogenicity based on studies utilizing MyD88-/- mice [95].  Nonetheless, it has been 
established that inclusion of caspase-1, IL-1β, or IL-18 encoding plasmids within vaccine 
formulations augments the adaptive response [121-123].  Moreover, immunological 
memory is heavily dependent on the production of select cytokines including IL-1β and 
IL-18 [124-127].  Hence, many vaccine formulations are supplemented with 
inflammatory cytokines to bolster the expansion and survival of memory T cell 
populations, suggesting that inflammatory signaling is at least partially required for DNA 
vaccine immunogenicity [125, 126].  Additionally, recent studies have identified the 
importance of cell death in vaccine immunogenicity, implying a possible role for 
pyroptosis in driving the immune response to DNA vaccination [128-130].  Therefore, 
study of the cytosolic DNA sensing AIM2 inflammasome would provide greater insight 
into the effects of inflammatory signaling on DNA vaccination. 
Research Framework and Objectives 
The data described above has laid the foundation for the original body of work 
described herein. While it has become increasingly accepted that DNA vaccines contain 
an intrinsic adjuvant effect that mediates their immunogenicity, the mechanisms 
governing such action remain largely unknown.  The aim of this dissertation is to provide 
a more complete understanding of the effects of the innate immune system on the 
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development of adaptive immune responses following DNA immunization.  In this 
regard, I will attempt to identify a common innate immune signaling pathway that 
regulates DNA vaccine immunogenicity using a pandemic influenza HA vaccine model 
(Figure 1.5).  Specifically, I will characterize the requirement of the IFN-αβ inducing 
cytosolic DNA sensor cGAS, as well as the downstream signaling molecules IRF3 and 
IRF7.  As little work has been done with regard to the pro-inflammatory machinery, I 
will also investigate the role of AIM2 in DNA vaccination.  This will be accomplished by 
utilizing novel multiplex technology to characterize serum cytokine and chemokine 
profiles, as well as more traditional immunological assays to quantify the adaptive 
immune response generated in various innate immune pathway knockout mice.  
Altogether, this work will provide a strong basis for understanding the mechanisms of 
action mediating DNA immunization. 
 As a secondary objective, in the final chapter of this dissertation, I will explore 
the role of innate immunity in aluminum adjuvants.  Several theories currently exist to 
explain the adjuvant effect of alum, all of which are incomplete.  The goal of these 
studies is to elucidate the importance of innate signaling on the antigen-specific antibody 
response elicited by inclusion of alum adjuvants, thereby providing a clearer 
understanding of the immunological mechanisms of alum and allowing for more 
scientifically informed decisions pertaining to future inclusion of vaccine adjuvants. 
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Figure 1.5:  DNA vaccine study design and immunization schedule. 
Mice were immunized intramuscularly with 100 µg codon optimized plasmid DNA 
encoding the full-length wild type HA protein from the pandemic 2009 H1N1 influenza 
(A/Texas/04/09).  Immunizations were divided between quadriceps, at 2 and 4 weeks.   
A third boosting immunization was delivered 1 week prior to sacrifice.  
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Chapter II 
 
IRF7 mediates DNA vaccine induced adaptive immune responses 
 
Introduction 
The most successful vaccines induce balanced, life long, protective immunity.  
Unlike many traditional inactivated/subunit protein based vaccines, DNA vaccines elicit 
not only humoral immunity (Yang, Kong et al. 2004), but also cellular immunity [49].  
Mechanistically, DNA plasmid uptake by cells allows for endogenous production and 
processing of encoded antigen, mimicking the benefits of live attenuated vaccines 
without the inherent risks.  Recent human trials have shown that DNA vaccines have the 
added benefit of generating elevated antibody responses directed against HIV-1 and 
pandemic influenza [17, 35, 43-45, 131] when compared to protein alone.  This may be 
attributed to reports that DNA vaccination is particularly effective in shaping germinal 
center B cell development [51], possibly through increased generation of T follicular 
helper cells. 
Many vaccine formulations contain multiple components that influence their 
immunogenicity.  In addition to the antigen of interest, an adjuvant element is usually 
included to augment the adaptive immune response [6, 132, 133].  Evidence hints that 
most clinically utilized adjuvants stimulate the innate immune system, and that these 
signals regulate the quality and longevity of the adaptive immune response [6, 133].  The 
ability of DNA vaccines alone to improve the humoral response suggests they contain an 
intrinsic adjuvant effect, the nature of which remains unclear.  
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Whereas the majority of adjuvants are TLR ligands, DNA vaccines appear to 
function independently of TLR signaling [81, 86, 108, 134].  Initial theories posited that 
the unmethylated CpG motifs encoded within the DNA vaccine plasmid would mediate 
immune responses via the endosomal DNA receptor, TLR9 [135].  However, both TLR9 
and MyD88-deficient mice mount immune responses comparable to wild-type mice, 
suggesting that multiple innate signaling pathways regulate DNA vaccination [94, 95].  
Current evidence suggests that the priming ability stems from the immunostimulatory 
double-stranded nature of the DNA plasmid itself, as cytosolic DNA is a potent inducer 
of type I interferon (IFN-αβ) via the stimulator of interferon gene (Sting) and the 
noncanonical IκB kinase, TANK binding kinase-1 (Tbk1) [56, 81]. Sting/Tbk1 activation 
triggers translocation of the interferon regulatory factor 3 (Irf3) and interferon regulatory 
factor 7 (Irf7) transcription factors into the nucleus, driving IFN-αβ production through a 
positive feedback loop. 
Studies have shown that Sting/Tbk1 mediated IFN-αβ production is required for 
DNA vaccine immunogenicity [81, 92, 95], however, the exact requirements of this 
pathway remain ambiguous as it has been reported that Irf3 deletion diminishes T cell 
immunity, but has little impact on B cell responses [136].  Furthermore, Shirota et al. 
reported no significant role for IFN-αβ in generating high-level antibody titers following 
DNA vaccination: in stark contradiction to both Tudor et al. and Ishii et al.’s findings 
[92, 95].  Additionally, the upstream DNA vaccine sensor has yet to be described, 
although multiple reports have identified the ubiquitously expressed cyclic GMP-AMP 
synthase (cGas) as a robust inducer of IFN-αβ capable of directly binding cytosolic 
dsDNA [86]. As cGas is vital for immunity to cytosolic DNA viruses and bacterial 
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infections [86, 91], we hypothesized that it would be essential for DNA vaccine 
immunogenicity. 
Here we investigate the role of Irf signaling in DNA vaccine immunogenicity.  
We quantified the effects of Irf3 and Irf7 deletion on both the innate and adaptive 
immune response. Interestingly, we identify Irf7 as being a key modulator in the 
generation of antigen-specific immune responses.  Furthermore, we examine the role of 
cGas in sensing DNA vaccine plasmid, as well as its necessity in DNA vaccination. 
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Results 
Sting is required for induction of both innate and adaptive immune responses to 
DNA vaccination. 
It was recently reported, using a model antigen, that Sting-deficient mice 
exhibited severe defects in the adaptive immune responses generated by DNA vaccines 
[81].  To confirm these results with a clinically utilized vaccine, we immunized mice with 
plasmid DNA expressing the HA antigen (pH1HA) of the influenza A virus which was 
responsible for the H1N1 pandemic in 2009.  As HA is highly immunogenic and the 
major protective antigen in clinically licensed inactivated and live-attenuated influenza 
vaccines, we reasoned that immune responses generated in the current study would be 
correlative of protective immunity [137-142].  
To gain a more complete understanding of the requirement for Sting signaling in 
innate immune responses, wild-type C57BL/6 (WT) and Sting-/- mice were immunized 
with the pH1HA vaccine and serum cytokines were measured six hours post 
immunization.  Quantification of innate cytokine levels revealed that Sting-/- mice had a 
marked decrease in TNF-α and IL-6 production, as previously described (Figure 2.1A,B) 
[143].  In agreement with the defect in innate signaling, Sting-deletion also negatively 
impacted the generation of antigen-specific adaptive immunity.  While WT mice yielded 
high levels of HA-specific IFN-γ secreting CD8+ T cells following stimulation with an 
MHC I peptide encoded within the pH1HA vaccine, Sting-/- splenocytes failed to respond 
to peptide stimulation (Figure 2.1C).  Furthermore, humoral responses were also 
impaired as immunized WT, but not Sting-/-, mice elicited robust anti-HA IgG responses 
(Figure 2.2A-B). Correspondingly, the HA-specific B cell population was decreased in 
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both the circulating (spleen) and memory (bone marrow) compartments of Sting-/- mice, 
as was the anti-HA binding avidity (Figure 2.2C-E). 
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cGas does not mediate the immune response to DNA vaccination. 
Previous attempts to identify the upstream sensor for DNA vaccination have been 
unsuccessful [94, 95].  It is widely believed that a cytosolic DNA sensor regulates IFN-
αβ production in response to DNA vaccination, and therefore vaccine immunogenicity.  
Several reports have identified cGas as a powerful activator of the Sting/Tbk1 pathway, 
providing a strong candidate for the unknown DNA vaccine sensor.  Hence, we evaluated 
its necessity in DNA immunization.  Initial in vitro studies utilizing bone marrow derived 
dendritic cells (BMDC) showed a marked decrease in IFN-β production upon transfection 
of pH1HA into the cytosol of cGas-/- cells (Figure 2.3).  Contrary to expectations, we did 
not observe an effect of cGas deletion in vivo in pH1HA immunized mice.  cGas-/- mice 
did not exhibit the characteristic decrease in pro-inflammatory cytokine production seen 
in Sting-/- mice (Figure 2.4).  Similarly, no significant change in the magnitude of the 
adaptive response was seen in immunized cGas-/- mice, as they had comparable humoral 
and cytotoxic T cell levels to WT mice (Figure 2.5A-D).  The ability of cGas-/- mice to 
generate high-level adaptive immune responses following DNA immunization suggested 
that IFN-αβ production was not inhibited by cGas deletion.  We therefore quantified local 
IFN-αβ production at the site of injection by taking punch biopsies at 6 and 12 hours post 
immunization. This ensured that we only measured pH1HA-induced IFN-αβ.  
Surprisingly, IFN-αβ production was attenuated in cGas-/- mice at the initial 6 hour time 
point.  However, the low levels of IFN-αβ in immunized cGas-/- mice recovered by the 12 
hour time point, approaching those seen in wild type controls (Figure 2.6).  These 
findings indicate that a secondary DNA sensing, IFN-αβ inducing pathway functions in 
cGas-/- mice, limiting the effects of cGas deletion on DNA vaccine immunogenicity. 
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Figure 2.5: DNA vaccine immunogenicity is cGas independent. 
WT and cGas-/- mice were immunized intramuscularly with a pH1HA encoding DNA 
vaccine at weeks 0 and 2.  (A) HA-specific total IgG and (B) IgG isotype titers were 
analyzed fourteen days post second immunization. Either (C) anti-HA antibody secreting 
cells or (D) the frequency of HA peptide-specific IFN-γ+ T were quantified cells in mice 
immunized with pH1HA 1week post third immunization. Splenocytes were stimulated 
with the CD8+ cell-restricted HA peptide (IYSTVASSL). Data are the averages ± SEM of 
5 mice. 

42
DNA vaccine induced adaptive immune responses are Irf3 independent. 
Although the effects of Sting deletion on DNA vaccine immunogenicity are clear, 
the mechanism by which Sting promotes IFN-αβ production is not.  Therefore, we 
dissected the downstream signaling molecules to elucidate the IFN-αβ pathway.  As Irf3 
is endogenously expressed at high levels and is required for initiating the IFN-αβ 
cascade, we analyzed its effects on DNA vaccine immunogenicity.  In vitro transfection 
of immortalized BMDM cultures showed a clear, negative effect of Irf3 deletion on IFN-
β production (Figure 2.7A-C).  As expected, the synthetic B-form dsDNA 
poly(deoxyadenylic-deoxythymidylic) and pH1HA induced robust IFN-β levels in Irf+/+ 
BMDM as measured by both rt-PCR and cell culture ELISA.  Conversely, IFN-β 
production was limited in Irf3-/- and, to a greater extent, Irf3/Irf7 double knockout (DKO) 
BMDM.  However, immunization of Irf3-/- mice did not result in impaired adaptive 
immunity.  WT and Irf3-/- mice had similar levels of IFN-γ producing CD8+ T cells, in 
contradiction to previously reported results (Figure 2.8A) [136].  Furthermore, Irf3-/- 
mice exhibited high levels of anti-HA IgG titers, a result not seen in DKO mice (Figure 
2.8B-D).  Overall, while IFN-αβ is required for DNA vaccine immunogenicity, Irf3 does 
not play a substantial role in generating adaptive immunity.  
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Irf7 regulates DNA vaccine-induced innate cell signaling. 
The failure of DKO mice to produce anti-HA adaptive immune responses 
following DNA vaccination suggests that Irf signaling is required for DNA vaccine 
immunogenicity. Because Irf3-/- mice were similar to WT controls, we next investigated 
Irf7 in the context of DNA vaccination.  As shown in Figure 2.9, both WT and Irf3-/- 
mice yielded commensurate levels of serum cytokines six hours post immunization.  
However, Irf7-/- and DKO mice showed clear defects in TNF-α and IL-6 production, 
yielding comparable levels to Sting-/- mice.   
The similar cytokine profiles seen in Sting-/- and Irf7-/- mice suggest that both are 
required for innate signaling following DNA vaccination.  Additionally, both molecules 
have been identified as key regulators of IFN-αβ production following DNA virus 
infection [79, 81].  As DNA vaccine immunogenicity is IFN-αβ dependent [95], we 
performed a thorough analysis of the effect of Sting and Irf7 deletion on IFN-αβ 
expression.  WT, Sting-/-, Irf7-/-, and DKO mice were immunized with the pH1HA 
vaccine, and punch biopsies were harvested as above.  rt-PCR analysis plainly illustrates 
that Sting-/- and DKO mice lack significant IFN-α and IFN-β expression compared to WT 
controls (Figure 2.10A,B). Interestingly, Irf7-/- mice exhibited a similar decrease in IFN-
αβ production, although to a lesser degree.  Consistent with impaired IFN-αβ production, 
both Sting-/- and Irf7-/- mice had a corresponding decrease in the IFN stimulated gene, 
IP10 illustrating the wide-ranging effect of Sting and Irf7 deletion on the innate immune 
response (Figure 2.10C).  
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Irf7 is required for generation of antigen-specific immune responses following DNA 
vaccination. 
Because Irf7-/- mice failed to produce high levels of pro-inflammatory cytokines 
and IFN-αβ, we reasoned that Irf7 deletion would inhibit development of antigen-specific 
immunity.  pH1HA vaccination of WT mice elicited strong antigen-specific humoral 
responses to the encoded HA antigen, whereas Irf7-/- mice failed to generate substantial 
levels of anti-HA IgG after two immunizations (Figure 2.11A,B).  Likewise, antibody-
binding avidity was decreased approximately 3 fold compared to WT controls (Figure 
2.11C), consistent with the lack of HA-specific B cells in both the spleen and bone 
marrow (Figure 2.11D,E).  Immunization of Irf7-/- mice also failed to induce significant 
numbers of IFN-γ+ CD8+ T splenocytes (Figure 2.11F).  Altogether, these results 
indicate that Irf7 plays a broad role in the activation of both T and B cell subsets 
following DNA vaccination. 
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following a 3rd boosting immunization. (D) Splenocyte B cells were plated immediately 
following isolation, while (E) bone marrow cells were plated after 5 days of culturing in 
non-specific stimulation to promote clonal expansion.  (F) Frequency of HA peptide-
specific IFN-γ+ T cells in mice immunized with pH1HA. Splenocytes were stimulated 
with the CD8+ cell-restricted HA peptide (IYSTVASSL). Data are the averages ± SEM of 
5 mice per group. *p<0.05, **p<0.01 versus control group. 
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Discussion 
The complicated interplay between DNA vaccination and the innate immune 
system is just beginning to be elucidated, as the canonical TLR pathways seem to have 
little influence on DNA vaccine immunogenicity.  Instead, current findings have shown 
that sensing of intracytoplasmic DNA plasmid governs DNA vaccine immunogenicity via 
the non-canonical Sting/Tbk1/IFN-αβ pathway.  However, the processes involved are the 
subjects of much disagreement.  In particular, the requirement for IFN-αβ in generating 
high-level antibody responses has yielded contradictory results.  Similarly, the necessary 
transcription factors downstream of Sting and Tbk1 remain uncertain.  This report 
provides a systematic investigation of these factors and gives a clearer understanding of 
the requirement for each in DNA vaccination. 
 Shirota et al. previously demonstrated the necessity for Irf3 in cellular mediated 
immune responses [136]. Supporting Shirota et al.’s findings, multiple reports have 
shown that Irf3-dependent IFN-β can augment the production of Th1 and Th2 cytokines 
both in vitro and in vivo [144, 145].  However, our results show no such requirement, 
with reductions in IFN-γ+ T cell numbers seen only in DKO mice.  Still, in agreement 
with Shirota et al.’s report, we did not see a substantial effect on humoral immunity, 
confirming that Irf3 is not required for B cell activation. The discrepancy in CD8+ T cell 
responses may be attributed to the inclusion of repeated immunizations in our study.  
Another possible explanation may be our choice of a more clinically relevant vaccine, as 
our immunogen has been optimized for development of antigen-specific responses. 
Regardless, our data suggests that Irf3 plays a limited role in DNA vaccination.  
In contrast to Irf3, our results did identify an unexpected role for Irf7 in DNA 
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vaccine immunogenicity.  Irf7-/- mice exhibited a similar immune phenotype to Sting-/- 
mice in that Irf7 deficiency resulted in significantly diminished T and B cell responses, 
indicating a broad contribution by Irf7 in the induction of adaptive immunity.  Moreover, 
Irf7-/- mice had impaired TNF-α and IL-6 production, characteristic of Sting dependent 
signaling.  The lack of IFN-αβ production in Irf7-/- mice further suggests that the defects 
in DNA vaccination seen in Sting-/- mice are due to a failure to initiate the Irf7-dependent 
IFN-αβ feedback loop.  This is in accordance with previous reports that Irf7 is the main 
regulator of immunity with regards to DNA virus infection [79, 146].  Altogether, our 
results indicate that Irf7 is the driving force behind sustained DNA vaccine-induced IFN-
αβ production, implying that the temporary defect in immune priming provided by Irf3 
deletion is overcome by the subsequent induction of Irf7, allowing for rescue of vaccine 
immunogenicity. 
Our attempt to identify the upstream DNA vaccine sensor yielded unforeseen 
results, as cGas deletion did not limit DNA vaccine immunogenicity.  In particular, the 
ability of cGas-/- mice to generate wild type IFN-αβ levels was unexpected.  Our results 
suggest that while cGas is required for the early induction of IFN-αβ, it is not necessary 
for sustained IFN-αβ production in response to DNA vaccine.  Previous studies have 
suggested that cGas is a non-redundant cytosolic DNA sensor [86, 147], but our data 
implies that at least one other sensor functions in parallel.  This provides a possible 
explanation for the ability of cGas-/- mice to generate adaptive immune responses 
following DNA vaccination. 
In conclusion, our results demonstrate that while Irf3 is not required for DNA 
vaccine immunogenicity, Irf7 is a key signaling molecule in DNA vaccination.  Irf7-/- 
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mice failed to generate broad vaccine-induced immune responses, exhibiting decreased 
serum IgG levels and T cell activity.  Unexpectedly, deletion of cGas did not dramatically 
impact the immune response, perhaps evidencing the redundant nature of cytosolic DNA 
receptors.  Overall, our results provide a deeper understanding of the cellular mechanisms 
through which DNA vaccines stimulate both the innate and adaptive immune pathways to 
promote immune responses directed against the encoded antigen. 
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Chapter III 
Identification of Aim2 as a sensor for DNA vaccines 
 
Introduction 
 The discovery of DNA vaccine technology in the early 1990s was a major event 
in the history of vaccinology due to the many unique features of DNA immunization, 
including its ability to elicit balanced antibody and T cell immunity [14, 15, 17, 137, 148, 
149].  However, in early clinical studies, the immunogenicity of DNA vaccines in 
humans was low when such vaccines were used alone.  More recent human trials have 
demonstrated that DNA vaccines are actually extremely powerful in priming the host’s 
immune system to develop high level protective antibody responses against HIV-1 and 
pandemic influenza viruses [17, 35, 43-45, 131].  Animal studies have further 
demonstrated that DNA immunization is effective in eliciting higher levels of antigen-
specific B cell responses [50]. One mechanism to achieve such an outcome is that DNA 
vaccination is effective in eliciting higher germinal center (GC) B cell development via 
enhanced follicular helper T (Tfh) cells for the production of high quality antibody 
responses [51]. 
 DNA vaccines produce immunogens in vivo, which are then presented to the 
immune system via the endogenous antigen processing pathways.  At the same time, the 
DNA plasmid itself confers an intrinsic adjuvant effect that enhances the immune 
response generated towards the vaccine-encoded immunogens [51, 150], but the 
intracellular processes involved remain to be fully elucidated.  Several pattern-
recognition receptors (PRRs) have been identified which respond to DNA molecules [59, 
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151].  One of the best-characterized DNA sensing PRRs is the endosomal TLR9, which is 
essential for the recognition of unmethylated CpG containing oligodeoxynucleotide 
(ODN) motifs commonly found in bacterial plasmids [76].  As DNA vaccine plasmid 
backbones contain certain CpG:ODN motifs, it was initially thought that TLR9 would be 
critical for DNA vaccine immunogenicity.  However, while DNA plasmid activates 
dendritic cells via TLR9, TLR9-deficient mice were able to mount immune responses 
comparable to wild-type mice [93, 94].  Likewise, DNA immunization of MyD88 and 
TRIF-deficient mice yields robust immune responses, further suggesting that TLR 
signaling may be dispensable for DNA vaccine induced immunogenicity [95]. 
 In recent years, it has become increasingly evident that the double-stranded nature 
of DNA itself functions as a potent activator of innate immune signals [56, 81, 86, 108, 
134].  Cytosolic DNA is a powerful initiator of type I IFN (IFN-αβ) in both immune and 
non-immune cells, functioning through a STING/TBK1/IFN-αβ dependent pathway that 
is independent of CpG motifs and TLRs.  At the same time, it is not clear whether other 
components of the innate immune system beyond the STING/TBK1/IFN-αβ pathway are 
involved in the immunogenicity of DNA vaccines [81, 95].  This is especially true in the 
case of inflammasome pathways.  Inflammasomes regulate caspase-1 activity, ultimately 
resulting in cleavage of the pro-inflammatory cytokines pro-IL-1β and pro-IL-18 into 
their active forms.  Inflammasome activation also results in pyroptotic cell death; a 
suicidal form of cell death characterized by the release of damage associated molecular 
patterns (DAMPs) that further propagates innate immune signaling to surrounding 
bystander cells [152].  One flavor of inflammasome contains absent in melanoma 2 
(Aim2), which is a direct sensor of cytosolic DNA and a member of the PYHIN family 
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[108].  Aim2 contains a DNA binding HIN200 domain, as well as a pyrin domain.  While 
Aim2’s role in orchestrating immune responses to both viral and bacterial pathogens is 
well characterized [115, 117, 153], the role of Aim2 in DNA vaccination is unknown. 
  Here we found that Aim2 and the adapter molecule Asc were required for the 
generation of optimal immunogen-specific antibody responses to a DNA vaccine 
expressing influenza HA immunogen in a mouse model.  DNA vaccination leads to 
transcription of key components of the inflammasome. Importantly, the efficacy of DNA 
vaccination was independent of IL-1β and IL-18. Surprisingly, Aim2-deficient mice were 
unable to elicit a type I IFN response at the site of injection. Our data therefore establish a 
novel role for Aim2 as a key player in the regulation of DNA vaccination. 
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Results 
 
DNA vaccine plasmid induces expression of Aim2, caspase-1 and the inflammasome 
 While previous studies have mainly used non-coding DNA plasmid or DNA 
vaccines coding for marker proteins to study DNA-elicited innate immune responses, the 
current study tested a DNA vaccine (pH1HA) expressing the HA antigen of the type A 
influenza virus subtype H1N1 virus which was responsible for a pandemic influenza in 
2009.  HA is the major protective antigen in clinically licensed inactivated and live-
attenuated influenza vaccines.  DNA vaccines expressing HA have been shown to be 
immunogenic in eliciting HA-specific antibodies in both animal and human studies [137-
142].  The expression of HA antigen by pH1HA used in the current study was confirmed 
by Western blot and its immunogenicity to elicit HA-specific antibody response was 
verified in a pilot mouse study (data not shown). 
 We first wanted to profile key immune response genes following DNA vaccine 
pH1HA using the Nanostring nCounter gene expression system, which includes a custom 
array encoding 50 innate immunity targets.  Gene induction was quantified from wild-
type C57BL/6 mice immunized with the pH1HA DNA vaccine.  Messenger RNA was 
isolated and the expression of innate immune genes profiled using the Nanostring 
nCounter, and changes in gene induction quantified.  Notably, Aim2 was induced ~6 fold 
within 12 hours of immunization when compared to naïve samples. Aim2 is a type I IFN 
inducible gene suggesting a potent ability of cells at the site of vaccination to recognize 
cytosolic plasmid vaccines (Figure 3.1A).  In accordance with the induction of Aim2, 
caspase-1 was also highly upregulated. (Figure 3.1B).  Most striking were the high levels 
59
of the inflammatory cytokines IL-1α and IL-1β (Figure 3.1C,D).  These observations 
indicate that inflammasome components were present at the site of vaccination. To test if 
the inflammasome pathway was active at the site of vaccination we utilized a caspase-1 
specific FAM/FLICA fluorescent stain to covalently label catalytically active caspase-1.  
Mature caspase-1 became apparent within 6 hours of immunization and reached a peak at 
12 hours (Figure 3.2).  Collectively, these results led us to examine the role of the Aim2 
inflammasome pathway in antigen specific immune responses elicited by pH1HA DNA 
vaccination. 
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Figure 3.1: Plasmid DNA vaccination induces the inflammasome. 
Inflammasome activation at the site of immunization was quantified by Nanostring 
nCounter analysis 12 hours post DNA immunization.  The site of injection was harvested 
and mRNA was isolated and expression levels were quantified for (A) Aim2, (B) caspase-
1, (C) IL-1α, (D) IL-1β.  Data are the averages ± SEM of 5 mice per group. *p<0.05, 
**p<0.01 versus control group. 
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Involvement of Aim2 in cellular responses to DNA vaccine plasmid 
 We first evaluated the ability of macrophages and dendritic cells to recognize 
pH1HA DNA vaccine by performing in vitro experiments. IL-1β production in response 
to pH1HA DNA vaccine was evaluated in BMDM collected from either Aim2+/+ or Aim2-
/- mice (Figure 3.3A).  As expected, both the synthetic B-form dsDNA 
poly(deoxyadenylic-deoxythymidylic) and pH1HA DNA vaccine induced a robust IL-1β 
response in Aim2+/+  BMDM as measured by ELISA.  However, IL-1β production was 
abolished in Aim2-/- BMDM.  Similar results were seen in BMDC (data not shown).  
Next, the pan-caspase inhibitor Z-VAD-FMK was included in BMDM cultures prior to 
adding pH1HA DNA vaccine (Figure 3.3B).  This resulted in inhibited IL-1β production 
in Aim2+/+ macrophages, yielding IL-1β levels comparable to Aim2-/- wells, supporting the 
role of Aim2 in DNA vaccine mediated IL-1β maturation.  Finally, pH1HA DNA vaccine 
induced an inflammatory form of cell death (pyroptosis) in Aim2+/+ macrophages, as 
measured by lactate dehydrogenase release (Figure 3.3C).  This response was attenuated 
in Aim2-/- cells.  Collectively, these data indicate that Aim2 acts as a sensor of DNA 
vaccine plasmid and regulates caspase-1 dependent IL-1β production and pyroptotic cell 
death in response to pH1HA DNA vaccines in vitro. 
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Figure 3.3: Aim2 is required for IL-1β production in response to DNA vaccines. 
LPS (200 ng/ml) primed Aim2+/+ and Aim2-/- BMDM were transfected with poly(dA-
dT) or DNA vaccine plasmid for 18 hrs. (A) Secreted IL-1β in the culture supernatants 
was analyzed by ELISA.  (B) Aim2+/+ and Aim2-/- BMDM were treated as above with 
the addition of the pan-caspase inhibitor Z-VAD-FMK and secreted IL-1β was quantified 
by ELISA.  (C) Aim2+/+ and Aim2-/- BMDM were treated as above, and culture LDH 
amounts were reported as a percentage of lysed cellular controls.  Data are presented as 
mean ± SEM from 3 independent experiments. **p<0.01, ***p<0.001,  ****p<0.0001 
versus control group. 
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Aim2 deletion impairs cytokine production following pH1HA immunization. 
 As it is evident that the Aim2 inflammasome recognizes and responds to pH1HA 
DNA vaccine in cultured cells, the role of Aim2 in pH1HA DNA vaccination was next 
examined in Aim2-deficient (Aim2-/-) and wild-type Aim2+/+ mice.  We first evaluated the 
effect of Aim2 deletion on innate cytokine signaling and the pro-inflammatory response.  
Following pH1HA immunization, Aim2-/- mice demonstrated a marked lack of the 
inflammatory cytokine IL-6 and the chemokines G-CSF, KC, and Rantes compared to 
Aim2+/+ controls, suggesting an inability of Aim2-/- to properly prime immune cell 
populations (Figure 3.4). 
Effects of Aim2 deletion on pH1HA induced HA-specific immune responses. 
 The marked decrease in cytokine production in Aim2-/- mice suggested a possible 
defect in the adaptive immune response to pH1HA vaccine.  Therefore, we next 
quantified the antigen-specific immune responses generated in Aim2-/- mice.  The pH1HA 
DNA vaccine induced high-level HA-specific antibody responses in Aim2+/+ mice, but 
significantly lower antibody titers in Aim2-/- mice (Figure 3.5A).  This reduction is 
isotype-independent as Aim2-/- mice exhibited significantly lower levels of HA-specific 
IgG1, IgG2b, and IgG2c responses (data not shown).  Likewise, Aim2-/- mice exhibited 
significantly reduced HA-specific circulating B cells as well as IFN-γ secreting CD8+ T 
cells in the spleen (Figure 3.5C,D).  The role of Aim2 in regulating the maturation 
process of pH1HA-induced antibody responses was further confirmed by measuring the 
avidity of serum HA-specific antibodies in these mice (Figure 3.5B).  Aim2+/+ mice 
required high concentrations of the chaotropic agent NaSCN to disrupt antigen/antibody 
complexes, while much lower concentrations of NaSCN were required for disassociation 
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in Aim2-/- mice.  To confirm the requirement for inflammasome signaling in DNA 
vaccine immunogenicity, we also quantified the adaptive response in Asc-/- mice.  Asc-
deletion similarly inhibited the generation of optimal HA-specific immune responses 
(Figure 3.6). 
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Figure 3.4: Aim2 is required for pro-inflammatory cytokine production in response 
to DNA vaccines. 
Serum chemokine levels of pH1HA immunized mice were measured 2 weeks prior to 
immunization and 6 hours post primary immunization via Luminex assay. (A) IL-6, (B) 
G-CSF, (C) KC, and (D) Rantes.  Data are the averages ± SEM of 5 mice per group. 
*p<0.05, **p<0.01,  ***p<0.001 versus control group. 
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Figure 3.5: Optimal DNA vaccine immunogenicity requires Aim2.  
Wild-type Aim2+/+ and Aim2-/- mice were immunized intramuscularly with a pH1HA 
encoding DNA vaccine at weeks 0 and 2.  (A) HA-specific IgG titers were analyzed 
fourteen days post second immunization.  Anti-HA binding avidity was quantified via 
ELISA and reported as molar concentration of sodium thiocyanate required to displace 
anti-HA serum antibodies to 2x pre-bleed levels (B).  For ELISPOT, spleens were 
harvested at termination 7 days following a 3rd boosting immunization. HA-specific 
antibody secreting B cells  (C) or IFN-γ secreting T cells (D) in mice immunized with 
either pH1HA or empty vector.  Splenocytes were stimulated with the CD8+ cell-
restricted HA peptide (IYSTVASSL). Data are the averages ± SEM of 5 mice per group. 
*p<0.05, **p<0.01,  ***p<0.001, ****p<0.0001 versus control group. 
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Figure 3.6: Asc is required for DNA vaccine immunogenicity. 
Wild-type C57BL/6 or Asc-/- mice were immunized intramuscularly with a pH1HA 
encoding DNA vaccine at weeks 0 and 2.  (A) HA-specific IgG titers were analyzed 
fourteen days post second immunization.  Spleens were harvested at termination 7 days 
following a 3rd immunization.  Frequency of HA-specific B cells (B) or IFN-γ+ T cells (C) 
were reported as spots per million splenocytes in mice immunized with pH1HA vaccine. 
Splenocytes were stimulated with the CD8+ cell-restricted HA peptide (IYSTVASSL). 
Data are the averages ± SEM of 5 mice per group. *p<0.05, **p<0.01 versus control 
group. 
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Aim2-deficient mice fail to cleave caspase-1 into its active form. 
 Since DNA vaccination resulted in high levels of caspase-1 activation in Aim2+/+ 
mice (Figure 3.2), we analyzed Aim2-/- mice for their ability to generate catalytically 
active caspase-1 using the FAM/FLICA assay (Figure 3.7).  Aim2-/- mice demonstrated a 
clear reduction in caspase-1 activation at the 12-hour peak time point when compared to 
Aim2+/+ controls. 
 
Effects of IL-1 and IL-18 deletion on vaccine induced HA-specific immune 
responses. 
 As inflammasome signaling ultimately results in the downstream cleavage of pro-
IL-1β and pro-IL18 into their respective active forms, the role of IL-1β and IL-18 
signaling in DNA vaccine was next investigated (Figure 3.8).  Surprisingly, both of these 
cytokines were dispensable for the DNA vaccine response as mice lacking the IL-1r or 
the IL-18r mounted normal vaccine responses.  Total serum HA-specific IgG titers were 
similar to wild-type C57BL/6 mice in both Il-1r-/- and Il-18r-/- mice.  Likewise, no 
significant difference was seen in total HA-specific B or CD8+ T cell numbers as 
measured by ELISPOT. This data is in line with previously published reports 
demonstrating little impact on DNA vaccination following MyD88 deletion [95]. 
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Figure 3.7: Aim2-deficient mice exhibit diminished caspase-1 activation at the site of 
immunization. 
(B) Wild-type Aim2+/+ and (C) Aim2-/- mice were immunized intramuscularly with 
pH1HA vaccine and caspase-1 activation was quantified by FAM/FLICA staining 12 
hours post immunization.  (A) PBS injected controls were utilized for comparison.  The 
site of injection was harvested and cryopreserved for tissue sectioning.  FAM/FLICA 
staining was visualized by confocal microscopy and is representative of 3 mice per group. 
Sections of 10 µm were stained with green fluorescent FLICA caspase-1 inhibitor. 
Nuclei were counterstained with DAPI. Low power resolution presented (Original 
magnification x 16). 
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Figure 3.8: IL-1β and IL-18 are dispensable for DNA vaccine immunogenicity. 
Wild-type C57BL/6, Il-1r-/-, and Il-18r-/- mice were immunized intramuscularly with a 
pH1HA encoding DNA vaccine at weeks 0 and 2.  (A) HA-specific IgG titers were 
analyzed fourteen days post second immunization.  Spleens were harvested at termination 
7 days following a 3rd immunization.  Frequency of HA-specific B cells (B) or IFN-γ+ T 
cells (C) were reported as spots per million splenocytes in mice immunized with pH1HA 
vaccine. Splenocytes were stimulated with the CD8+ cell-restricted HA peptide 
(IYSTVASSL). Data are the averages ± SEM of 5 mice per group. 
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The immune response is lineage dependent. 
 Previously published data has demonstrated the requirement for both 
hematopoietic and non-hematopoietic cell lineages in DNA vaccination [95].  To further 
elucidate the role of Aim2, bone marrow chimeric mice were generated by transferring 
bone marrow from Aim2+/+ mice into Aim2-/- mice, or vice versa (Figure 3.9).  Aim2+/+ 
and Aim2-/- mice reconstituted with Aim2-/- bone marrow exhibited strong defects in both 
the T cell response and HA-specific IgG production.  Interestingly, transfer of Aim2+/+ 
bone marrow into Aim2-/- rescued the T cell response, but only partially rescued the 
humoral response.  While HA-specific IgG levels were impaired compared to Aim2+/+ 
mice reconstituted with Aim2+/+ bone marrow, they were significantly higher than Aim2-/- 
bone marrow reconstituted mice.  This would support that Aim2 is required in both the 
hematopoietic and non-hematopoietic lineages for optimal humoral responses, but 
deficiency in non-hematopoietic lineages does not affect CD8+ T cell responses. 
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Figure 3.9: Contribution of hematopoietic and non-hematopoietic cells to DNA 
vaccine induced immunogenicity. 
Bone marrow chimeric mice were immunized with a pH1HA vaccine as described in 
Figure 2.  Fourteen days post second immunization, sera from chimeric mice were 
analyzed for HA-specific IgG titers (A).  Spleens were harvested at termination 7 days 
following the 3rd immunization.  Frequency of HA-specific B cells (B) or IFN-γ+ T cells 
(C) were reported as spots per million splenocytes in mice immunized with pH1HA 
vaccine.  Splenocytes were stimulated with the CD8+ cell-restricted HA peptide 
(IYSTVASSL). Data are the averages ± SEM of 5 mice per group. *p<0.05, **p<0.01,  
***p<0.001 versus control group. 
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Aim2-/- mice lack IFN-αβ signaling. 
 The failure of Aim2-/- mice to generate optimal adaptive immune responses 
implies a defect in immune priming at the site of injection.  While the major function of 
the Aim2 inflammasome is to regulate caspase-1 activation, resulting in IL-1β, IL-18 and 
cell death pathways, our data indicate that IL-1β and IL-18 are not responsible for the 
Aim2 dependent effects we observed. We therefore endeavored to quantify IFN-α/β as it 
has been reported to play a key role in the immune response to B-DNA [56-58, 154].  In 
addition, it has been established that IFN-α/β signaling is required for DNA vaccination 
[81, 95].  Aim2 does not control DNA induced IFN-α/β production directly.  Rather the 
STING pathway mediates these effects. Since the IFN-α/β response is so critical for DNA 
vaccination, we performed a detailed kinetic analysis measuring IFN-α/β expression in 
Aim2+/+ and Aim2-/- mice.  To ensure we only detect DNA vaccine-induced IFN-α/β, we 
limited our measurements to the site of immunization.  Aim2+/+ and Aim2-/- mice were 
immunized with the pH1HA DNA vaccine, and punch biopsies were collected from the 
site of injection.  Quantitative rt-PCR analysis of mRNA clearly shows that Aim2-/- mice 
have reduced IFN-α and IFN-β expression compared to Aim2+/+ controls, with expression 
peaking at 12 hours post immunization in wild-type mice (Figure 3.10).  Intriguingly, 
IFN-αβ expression in Aim2-/- mice peaked at 6 hours post immunization and remained 
static throughout the time course.  Consistent with the decrease in IFN-α/β, there was a 
corresponding decrease in the IFN stimulated gene, IP10.  We also noticed a significant 
decrease in TNF.  As the development of cellular and humoral immunity was cell lineage 
dependent, we quantified IFN-α/β levels in Aim2 bone marrow chimeric mice to 
determine the requirement for Aim2 in cellular lineages with regards to IFN-α/β 
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production (Figure 3.11).  Notably, Aim2-deletion in both the hematopoietic and non-
hematopoietic populations resulted in impaired local IFN-α/β production following DNA 
vaccination.  Reconstitution with Aim2+/+ bone marrow failed to rescue IFN-α/β 
production, and no significant difference in IFN-α/β levels was seen between mice with 
wild-type Aim2 in the hematopoietic or non-hematopoietic populations, suggesting that 
both cellular lineages regulate innate immune responses. 
 Asc-/- mice had similar levels of IFN-α/β, further confirming the requirement for 
inflammasome signaling (Figure 3.12).  These data suggest a previously unreported role 
for Aim2 in regulating local IFN-α/β levels following DNA vaccination.  As Aim2 
controls cell death at the site of infection, it is likely that Aim2 dependent cell death 
liberates endogenous DAMP danger signals, which might in turn elicit IFN-α/β via the 
Aim2-independent STING/TBK1 pathways. This broad defect in IFN-α/β signaling likely 
explains the defects we observed in Aim2-deficient mice treated with DNA vaccines.   
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Figure 3.10: Aim2-deficiency limits IFN-αβ production at the site of injection. 
Aim2 +/+ and Aim2-/- mice were immunized intramuscularly with pH1HA vaccine, and the 
site of injection was harvested at various time points.  Total RNA was isolated from 
tissue biopsies and subjected to rt-PCR for (A) IFN-α, (B) IFN-β, (C) IP10, and (D) TNF.  
Reported expression levels are relative to expression in naïve Aim2 +/+ mice.  Data are the 
averages ± SEM of 5 mice per group. *p<0.05, **p<0.01,  ***p<0.001, ****p<0.0001 
versus control group. 
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Figure 3.11: Aim2 is required in both hematopoietic and non-hematopoietic 
populations for IFN-αβ production at the site of injection. 
Aim2 +/+ and Aim2-/- mice were immunized intramuscularly with pH1HA vaccine, and the 
site of injection was harvested at various time points.  Total RNA was isolated from 
tissue biopsies and subjected to rt-PCR for (A) IFN-α, (B) IFN-β, and (C) IP10.  Reported 
expression levels are relative to expression in naïve Aim2 +/+/ Aim2 +/+ mice.  Data are the 
averages ± SEM of 5 mice per group. *p<0.05, **p<0.01,  ***p<0.001 versus control 
group. 
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Figure 3.12: Asc is required for DNA vaccine induced IFN-αβ production. 
WT C57BL/6 and Asc-/- mice were immunized intramuscularly with pH1HA vaccine, and 
the site of injection was harvested 12 hours later.  Total RNA was isolated from tissue 
biopsies and subjected to rt-PCR for IFN-α, IFN-β, IP10.  Data are the averages ± SEM 
of 5 mice per group. **p<0.01,  ***p<0.001 versus control group. 
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Discussion 
 The innate immune pathways governing DNA vaccination remain to be fully 
characterized.  Recent reports have established the STING/TBK1/IFN-αβ axis as required 
for DNA vaccine immunogenicity [81, 95]; however, the PRR(s) required for IFN-αβ 
production remain to be identified in this context.  Likewise, the involvement of other 
innate immune signaling pathways is unclear.  In particular, the requirement for the 
inflammasome signaling machinery in DNA vaccine elicited antigen-specific immune 
responses has not been examined.  Here, we identified the Aim2 inflammasome as a 
DNA vaccine sensor with the ability to regulate the antigen-specific adaptive immune 
response.  Whereas previous reports have focused on downstream signaling molecules, 
this is the first report to identify a DNA sensor that is required for DNA vaccine 
immunogenicity. 
 The failure of Aim2-/- mice to generate optimal adaptive immune responses 
implies a defect in immune priming at the site of injection.  While the function of Aim2 
has been well characterized, how and where Aim2 interacts with the vaccine plasmid 
remains unclear.  Interestingly, immunization of bone marrow chimeras revealed varying 
degrees of necessity for Aim2 signaling in both the hematopoietic and non-hematopoietic 
lineages.  Aim2 is required in both cell lineages for optimal humoral responses, as 
chimeric mice lacked high levels of anti-HA antibodies. This may be attributed to 
impaired IL-6 production in Aim2-/- mice possibly limiting B-cell survival and CD4+ T 
cell expansion as has been reported in several studies (Figure 3.4) [155].  In addition, 
recent reports have described the effect of DNA priming on T follicular helper cell 
generation [51].  Even more surprising, Aim2-deletion in non-hematopoietic cells did not 
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impact CD8+ T cell responses, as mice reconstituted with Aim2+/+ bone marrow presented 
similar levels of IFN-γ to Aim2+/+.  This provides further evidence for a defect in immune 
cell priming. 
 Of note, deletion of IL-1β and IL-18 signaling in DNA vaccination did not impact 
DNA vaccine immunogenicity, confirming previous reports describing minimal effect of 
MyD88 deletion on DNA vaccine immunogenicity [156].  This stands in stark contrast to 
the importance of IL-1β and IL-18 inflammatory signaling in the early stages of pathogen 
infection.  Why IL-1β and IL-18 signaling are dispensable remains unclear, but one 
possible reason is the highly immunostimulatory nature of the DNA vaccine plasmid 
itself, as DNA is a potent inducer of both IFN-α/β and several NFκB regulated immune 
genes.  In addition, the level of several chemokines, such as MIP-1α/β and MCP-1, 
remained unchanged (data not shown), allowing for recruitment of monocyte and 
lymphocyte populations.   
 Most intriguingly, the reduction of IFN-α/β levels at the site of immunization in 
Aim2-/- suggests a previously unknown relationship between Aim2 and local IFN-α/β 
production.  IFN-α/β induction also appears to be lineage independent, as deletion of 
Aim2 in either cell lineage attenuated IFN-α/β production.  Aim2 is not known to mediate 
IFN-α/β production directly, hinting at an indirect link between these two divergent 
pathways.  We propose that decreased pyroptotic cell death in Aim2-/- mice results in 
diminished DAMP release, limiting cellular signaling and bystander cell activation.  The 
release of cellular DNA by pyroptotic cells may augment IFN-α/β production by 
surrounding cells, possibly through the STING/TBK1 signaling axis, further propagating 
the immune response.    
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 In conclusion, our results indicate that Aim2 plays a significant role in DNA 
vaccination.  Aim2-/- mice failed to generate optimal immune responses upon DNA 
vaccination, exhibiting decreased serum IgG levels and T cell cytokine production, 
demonstrating the necessity for Aim2 signaling in DNA vaccine immunogenicity.  In 
addition, we report a previously unknown function for Aim2 in augmenting IFN-α/β 
production at the site of immunization.  Our results provide a deeper understanding of the 
cellular mechanisms through which DNA vaccines stimulate both the innate and adaptive 
immune pathways to enhance the immune responses targeting the encoded antigen. 
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Preface to Chapter IV 
John Joseph Suschak III performed and analyzed all experiments in this chapter. 
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Chapter IV 
 
The role of AIM2 in alum adjuvanticity 
 
4.1 Role of Adjuvants in Vaccination.  
As discussed, vaccination is a key aspect of public health. Unfortunately, it is 
sometimes necessary to sacrifice immunogenicity for safety.  For instance, subunit and 
inactivated vaccines tend to induce lower levels of immunity for a significantly shorter 
term than live-attenuated vaccines, but they do not have the safety risks associated with 
immunocompromised individuals.  To combat this issue, many vaccine formulations 
include adjuvants to enhance humoral and effector T cell functions.  Adjuvants represent 
a diverse group of compounds that can both vastly improve the immunogenicity of a 
vaccine and modulate the immune response.  While adjuvants have traditionally been 
used to amplify the adaptive response, another aspect has become increasingly important: 
adjuvants can shape the immune response to one that is most effective for a given 
pathogen.  Adjuvants have been used to: (1) skew the immune response towards the 
appropriate type (e.g. Th1 versus Th2); (2) increase breadth and specificity [157, 158]; 
and (3) facilitate the generation of a memory repertoire [159].  Indeed, adjuvant choice is 
a crucial component of vaccine formulation research and development. Despite the 
widespread inclusion of adjuvants in vaccine formulations, understanding of their 
immunological mechanisms remains incomplete. 
4.1.1 Vaccine Formulations with Aluminum Salt Adjuvants. 
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Alexander Glenny first reported the ability of aluminum salts to significantly 
enhance the antibody response in guinea pigs immunized with soluble toxoid [160].  
Since then, aluminum salts (colloquially known as “alum”) have become the most 
clinically relevant and widely used adjuvant in licensed vaccines.  Although the search 
continues for alternative adjuvants, aluminum adjuvants continue to be used due to their 
excellent track record of tolerability and adjuvanticity with a variety of antigens.  Several 
alum formulations exist, but the most popular is aluminum phosphate or aluminum 
hydroxide gel, also known as Alhydrogel®. Another commonly used formulation is 
Imject® alum, a gel formulation of aluminum hydroxide and magnesium hydroxide.  
Other proprietary formulations exist, but they are considerably less common. 
Aluminum adjuvants are utilized in several vaccine formulations, particularly 
those administered to children.  The diphtheria-tetanus-acellular pertussis vaccine 
(commonly referred to a s DTaP), Hepatitis B, and human papillomavirus vaccines all 
contain aluminum salts.  Aluminum hydroxide gel has also been employed in two 
successful HIV-1 vaccine clinical trials, VaxGen and RV144.  RV144 is especially 
noteworthy in that it was the first HIV-1 vaccine to demonstrate protection in high-risk 
individuals [28, 161]. 
4.2. Cellular Mechanism for Alum Adjuvanticity. 
The goal of vaccination is to induce long term immunity while minimizing side 
effects.  The choice of adjuvants has traditionally been made empirically due to their 
effects on the adaptive immune response.  This holds especially true for alum, which is 
generally chosen for its ability to boost humoral responses with little reactogenicity. Yet, 
the mechanism of alum’s adjuvant effect remains unclear, owing to inconsistent study 
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results.  Several models exist, but none have been conclusively proven.  The 
disagreement between study data may be attributed to differences in alum formulation 
and route of immunization.  Therefore, further investigation is required. 
4.2.1. Antigen Depot Effect. 
Originally, it was postulated that alum provided an antigen depot effect, whereby 
alum absorbed antigen is slowly released, improving uptake by APCs.  Intraperitoneal 
injection of alum results in aluminum depots that can last up to one month.  Dendritic 
cells and antigen specific T cells accumulate around this depot, suggesting that the 
antigen depot is involved in maintenance of the memory pool [162].  However, this effect 
is site of immunization dependent, as both intramuscular and subcutaneous injection 
result in rapid alum/antigen complex disassociation [163].  Furthermore, it has been 
demonstrated that adsorption of antigen onto alum is not required for adjuvanticity [164, 
165].  In fact, characterization studies of HIV-1 gp120 antigen formulated with a variety 
of aluminum hydroxide compounds showed that gp120 is rapidly desorbed from the 
adjuvant following immunization of guinea pigs, rabbits, and baboons [164].  These data 
suggest a fundamental difference in alum depot functionality depending on the site of 
injection and the local environment. 
4.2.2 Aluminum Adjuvants and the Inflammasome. 
The cellular signaling pathways governing APC activation and humoral immunity 
following alum immunization have only recently begun to be addressed.  A hallmark of 
alum immunization is the release of high levels of the pro-inflammatory cytokines IL-1β 
and IL-18.  This has led several groups to explore the effect of the pro-inflammatory 
NOD like receptors on alum adjuvanticity.  The NOD like receptors trigger 
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inflammasome assembly in response to microbial pathogens as well as DAMPs.  The 
NOD like receptor 3 (NLRP3) is activated by a wide range of PAMPs as well as DAMPs, 
including ATP, nigericin, cholesterol, uric acid, silica, and amyloid-β [166-169].  As with 
all inflammasome receptors, NLRP3 forms a molecular platform with ASC and caspase-
1, resulting in IL-1β and IL-18 activation.  NLRP3 also results in caspase-1 dependent 
pyroptosis. 
It has been reported that alum adjuvant signals through NLRP3 inflammasome to 
stimulate inflammatory dendritic cells in vitro [170-172].  However, in vivo studies have 
yielded contradictory results.  In vivo studies in Asc, caspase-1, and Nlrp3-deficient mice 
failed to elicit antigen-specific antibody responses, suggesting that inflammasome 
signaling is critical for adaptive immunity raised by aluminum salt adjuvants.  In an in 
vivo immunization model utilizing OVA antigen, the induction of OVA-specific IgG1 by 
alum required assembly and activation of the NLRP3 inflammasome.   Meanwhile, 
concurrent studies confirmed that alum activates IL-1β and IL-18 via the NLRP3 
pathway, but argue that NLRP3 is of little importance to the adaptive response.  Studies 
by Li et al. supported the above evidence [173], but independent groups reported that 
while alum activation of the NLRP3 inflammasome was critical for OVA-specific T cell 
responses, it was unessential for humoral immunity [174-176].  Still other studies 
reported no impact of either caspase-1 or NLRP3 activation on the specific CD8+ T cell, 
CD4+ T cell, antibody, or Th2-biased responses after alum-adjuvanted vaccination with 
model antigens [177].   
Interestingly, the question remains if aluminum salts act directly or indirectly to 
trigger innate sensors.  Perhaps the most compelling argument for alum’s adjuvant effect 
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centers on its cytotoxic effects [178].  Apoptotic cells release a plethora of endogenous 
danger-associated molecular pattern (DAMPs), which prime the immune system via 
innate PRR signaling [63].  Early evidence supported a direct mechanism involving 
particulate phagocytosis and subsequent lysosomal disruption releasing DAMPs into the 
extracellular space [167, 171, 176].  More recent studies by Marichal et al, using a novel 
approach, show that alum injection results in the cytotoxic release of host DNA, which 
mediates the adjuvant activity of alum via a TBK1-dependent IFN pathway [128, 129, 
177].  It remains to be seen if the cytotoxic release of cellular DNA also stimulates the 
pro-inflammatory response, and to what extent this impacts adjuvanticity.  Specifically, 
as several reports have identified the requirement for the inflammasome and IL-1β, it 
stands to reason that the cytosolic DNA sensor AIM2 may play a role in alum adjuvanted 
immune responses, but this has yet to be addressed. Here, we report that alum treatment 
triggers the AIM2 inflammasome, and the subsequent inflammatory signaling is required 
for optimal vaccine-induced immunity.  Furthermore, AIM2 at least partially regulates 
the induction of IFN-αβ at the site of alum immunization.  Therefore, we have established 
a novel role for AIM2 as a key player in alum adjuvanticity. 
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Results 
Alum adjuvant activates the Aim2 inflammasome. 
Marichal et al. reported that the cytotoxic release of cellular DNA mediated the 
adjuvant effects of alum through bystander cells [129].  We therefore hypothesized that 
the release of endogenous DNA by alum treated cells would stimulate the pro-
inflammatory cytosolic DNA receptor, AIM2.  We first evaluated the ability of BMDM 
harvested from either Aim2+/+ or Aim2-/- mice to produce IL-1β following alum treatment 
in vitro (Figure 4.1).  As expected, both the synthetic B-form dsDNA 
poly(deoxyadenylic-deoxythymidylic) and alum induced a robust IL-1β response in 
Aim2+/+ macrophages.  Yet, IL-1β was almost completely absent from Aim2-/- cultures. To 
ensure that IL-1β cleavage was inflammasome dependent, the pan-caspase inhibitor Z-
VAD-FMK was added to BMDM cultures prior to alum stimulation.  The addition of Z-
VAD-FMK resulted in significantly decreased IL-1β activation in Aim2+/+ macrophages, 
to levels comparable to Aim2-/- wells, indicating that the inflammasome regulates caspase-
1 dependent IL-1β maturation in response to alum adjuvant. 
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Aim2 is required for optimal B cell responses in TIV + alum immunized mice. 
As it is evident that the Aim2 inflammasome recognizes and responds to the 
release of endogenous DNA by alum treated cells in culture, we tested the ability of alum 
to adjuvant the adaptive immune response generated by the seasonal trivalent inactivated 
influenza vaccine (TIV).  Previous studies have mainly used model antigens absorbed 
onto alum to study adjuvanticity. We chose to utilize the clinically relevant TIV as it has 
been shown to be immunogenic in eliciting HA-specific antibodies in both animal and 
human studies.  HA is the major protective antigen in clinically licensed inactivated and 
live-attenuated influenza vaccines, and serves as a clear target for immunological assays.  
Aim2+/+ and Aim2-/- mice were immunized with either the seasonal TIV alone or TIV 
absorbed onto alum according to the schedule shown in Figure 4.2.  Anti-HA antibodies 
were detected in both Aim2+/+ and Aim2-/- mice immunized with TIV alone.  HA-specific 
IgG and IgG1 levels were significantly boosted in wild-type Aim2+/+ mice immunized 
with alum absorbed TIV.  In stark contrast, Aim2-/- mice failed to respond to alum 
inclusion, yielding antibody titers similar to those seen in TIV alone mice (Figure 4.3A-
C).  Further confirming a defect in B cell activation, TIV + alum immunized Aim2-/- mice 
had significantly fewer HA-specific B cells in both the spleen and bone marrow.  Aim2 
also appears to play a role in regulating the antibody maturation process as Aim2-/- mice 
demonstrated impaired antibody avidity (Figure 4.3D-F).  Aim2+/+ mice required high 
concentrations of the chaotropic agent NaSCN to disrupt antigen/antibody complexes, 
while much lower concentrations of NaSCN were required for disassociation of Aim2-/- 
sera.  All together, this data suggests that Aim2 deficiency results in impaired quality of 
antigen-specific, alum-adjuvanted antibody responses. 
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Figure 4.2:  Study design and immunization schedule. 
Mice received either 1.5 ug Aventis Pasteur Fluzone 2004-2005 trivalent inactivated 
vaccine (TIV) alone or absorbed onto 65 ug Alhydrogel®, divided between quadriceps, at 
2 and 4 weeks.  A third boosting immunization was delivered 1-week prior to sacrifice. 
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Figure 4.3: Alum adjuvanted humoral responses require Aim2.  
Wild-type Aim2+/+ and Aim2-/- mice were immunized intramuscularly with either TIV 
alone or TIV absorbed onto alum at weeks 0 and 2.  (A) Peak level of pooled sera (5 mice 
per group).  Arrows represent points of immunization.  HA-specific IgG titers (B), 
including their (C) isotypes, were analyzed fourteen days post second immunization. 
Splenocytes and bone marrow were harvested at termination 7 days following a 3rd 
boosting immunization.  (D) Splenocyte B cells were plated immediately following 
isolation, while (E) bone marrow cells were plated after 5 days of culturing in non-
specific stimulation to promote clonal expansion.  Anti-HA binding avidity was 
quantified via ELISA and reported as molar concentration of sodium thiocyanate required 
to displace anti-HA serum antibodies to 2x pre-bleed levels (F).  Data are the averages ± 
SEM of 5 mice per group. *p<0.05, **p<0.01,  ***p<0.001, ****p<0.0001 versus 
control group. 
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Aim2-mediated alum signaling is lineage dependent. 
The necessity of Aim2 inflammasome signaling in diverse cell lineages remains 
to be determined.  As such, we generated bone marrow chimeric mice by transferring 
bone marrow from Aim2+/+ mice into Aim2-/- mice, or vice versa (Figure 4.4).  Both 
Aim2+/+ and Aim2-/- mice reconstituted with Aim2-/- bone marrow exhibited strong defects 
in antigen-specific IgG production.  Interestingly, reconstitution with wild-type Aim2+/+ 
bone marrow fully rescued the anti-HA IgG response, an effect not seen in mice 
reconstituted with Aim2-/- bone marrow.  Moreover, total HA-specific B cell numbers 
were decreased only in mice receiving Aim2-/- bone marrow, providing further evidence 
that inflammasome-dependent APC priming is an integral component of alum adjuvants.   
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Aim2-/- mice lack IFN-αβ signaling. 
TBK1 mediated IFN-αβ production has been reported to play a central role in 
alum adjuvanticity [129].  The Aim2 inflammasome regulates IL-1β, IL18, and 
pyroptosis via caspase-1 activation. As IFN-αβ is required for alum-mediated adaptive 
immunity, we quantified IFN-αβ expression in Aim2+/+ and Aim2-/- mice.  To ensure we 
detect only alum/TIV-induced IFN-αβ, we limited our measurements to the site of 
immunization.  Aim2+/+ and Aim2-/- mice were immunized with the alum/TIV complex, 
and punch biopsies were collected from the site of injection.  rt-PCR analysis of Aim2-/- 
mRNA shows a clear reduction in IFN-α and IFN-β expression at 12 hours when 
compared to Aim2+/+ controls (Figure 4.5), suggesting a previously unreported role for 
Aim2 in regulating local IFN-αβ levels following alum administration.  Since Aim2 
controls cell death at the site of infection, it is possible that Aim2 dependent cell death 
releases endogenous danger signals, which might in turn elicit IFN-α/β via the Aim2-
independent STING/TBK1 pathways.  This likely explains the defects we observed in 
Aim2-deficient mice treated with alum adjuvant. 
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Discussion 
The role of innate immune signaling in aluminum adjuvanticity remains unclear.  
Specifically, the impact of the inflammasome on elicitation of antigen-specific adaptive 
immune responses following alum immunization is poorly defined. Whereas previous 
reports have attributed alum’s adjuvant effects to the NLRP3 inflammasome, our results 
indicate that alum also triggers Aim2-dependent IL-1β release, suggesting that Aim2 is at 
least partially required for APC activation. 
We found that the Aim2 inflammasome is required for generation of high-level 
antibody responses following TIV + alum immunization.  Aim2-/- mice exhibited antibody 
levels that were similar to those of animals immunized with TIV alone. The failure of 
Aim2-/- reconstituted chimeric mice to generate robust antigen-specific humoral responses 
implies the defect is primarily in hematopoietic cells.  The mechanism of action remains 
unknown, but as alum rapidly associates with free host DNA [179], it can efficiently 
deliver DNA to the cytosol where it is detected by Aim2, driving the inflammatory 
response required for generation of immunological memory [124-127].  
Most intriguingly, the reduction of IFN-αβ levels at the site of immunization in 
Aim2-/- mice suggests a relationship between Aim2 and local IFN-αβ production. We 
propose that decreased pyroptotic cell death in Aim2-/- mice results in diminished DAMP 
release, limiting cellular signaling and bystander cell activation.  The release of cellular 
DNA by pyroptotic cells may augment IFN-αβ production by surrounding cells, 
propagating the immune response.   Marichal et al have previously proposed a model in 
which self-DNA induces high levels of IgG1 via highly active Th effectors [129].  Aim2 
pyroptotic DAMP release may contribute to this pathway, elevating the IgG response 
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even further. 
In conclusion, our results indicate that Aim2 plays a significant role in alum 
adjuvanticity.  Aim2-/- mice failed to generate high-level antibody responses following 
TIV + alum immunization.  In addition, we report a previously unknown function for 
Aim2 in augmenting IFN-α/β production at the site of alum immunization.  Of note, our 
results are in disagreement with Kool et al and Franchi et al, who reported a limited role 
for the inflammasome in IgG production, which is most likely attributed to our use of IM 
injection as opposed to intraperitoneal injection.  Furthermore, while we have identified 
Aim2 as a player in alum adjuvanticity, we cannot discount the role of NLRP3.  The 
impact of each inflammasome may be route of immunization dependent.  It is probable 
that both pathways work in concert to drive the pro-inflammatory cascade.  DAMP 
release contributes not only to the TBK1/IFN-αβ pathway, but also to memory cell 
generation via inflammatory signals.  Our results provide a deeper understanding of the 
cellular mechanisms through which alum stimulates both the innate and adaptive immune 
pathways to enhance humoral responses.  
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Chapter V 
DNA Vaccine Materials and Methods 
Cell Culture and Stimulation 
Irf+/+, Irf3-/-, and Irf3-/-/Irf7-/- (DKO) immortalized BMDM were generated in 
house (UMMS).  LPS was treated at a concentration of 200 ng/ml.  Poly (dA:dT) (Sigma 
Aldrich) DNA and H1-TX04-09.tPA DNA vaccine plasmid were transfected using 
Lipofectamine 2000 at a concentration of 1.5 µg/ml.  Cultures were incubated 16-18 
hours at 37 o C, and supernatants were harvested.  Murine IFNβ sandwich ELISA was 
used as previously described.  IFN-α, IFN-β, rt-PCR was performed on RNA was isolated 
from immortalized BMDM.  cDNA was then used for rt-PCR reactions on a Bio-Rad 
CFX-96 cycler.  Primers sequences are available upon request. 
 Mouse BMDC were generated from Aim2+/+ or Aim2-/- mice by culturing fresh 
bone marrow in R10 medium containing GM-CSF for 8 days at 37 o C.  Aim2+/+ and 
Aim2-/- immortalized BMDM were produced in house.  Cells were first primed with 200 
ng/ml LPS (Sigma Aldrich) for 4-5 h prior to treatment with appropriate stimuli. All 
media was removed from the cells, and the appropriate stimulus was added.  Poly 
(dA:dT) (Sigma Aldrich) DNA and H1-TX04-09.tPA DNA vaccine plasmid were 
transfected using Lipofectamine 2000 at a concentration of 1.5 µg/ml.  ATP was added at 
a concentration of 1.25 µg /ml.  Cultures were incubated 16-18 hours at 37 o C, and 
supernatants were harvested.   
Cell Culture Cytokine ELISA 
Irf+/+, Irf3-/-, and DKO immortalized BMDM were generated in house (UMMS).  
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LPS was treated at a concentration of 200 ng/ml.  Poly (dA:dT) (Sigma Aldrich) DNA 
and H1-TX04-09.tPA DNA vaccine plasmid were transfected using Lipofectamine 2000 
at a concentration of 1.5 µg/ml.  Cultures were incubated 16-18 hours at 37 o C, and 
supernatants were harvested.  Murine IFNβ sandwich ELISA was used as previously 
described.  IFN-α, IFN-β, rt-PCR was performed on RNA was isolated from 
immortalized BMDM.  cDNA was then used for rt-PCR reactions on a Bio-Rad CFX-96 
cycler.  Primers sequences are available upon request. 
 Cell culture supernatants were assayed for IL-1β (BD Biosciences, Franklin 
Lakes, NJ) by ELISA. Lactate dehydrogenase (LDH) release was used to measure 
pyroptotic cell death.  LDH assays were performed using the Promega CytoTox96 Non-
radioactive Cytotoxicity Kit according to manufacturer’s directions (Promega, Madison, 
WI) 
Mice 
C57BL/6 mice were obtained from Taconic Laboratories. Sting-/- mice were a gift 
from G. Barber (University of Miami).  Irf3-/-, Irf7-/-, Irf3-/-/Irf7-/- (DKO), and cGas-/- mice 
were generated in house by K. Fitzgerald group at the University of Massachusetts 
Medical School (UMMS).  All mice were maintained in the Department of Animal 
Medicine at UMass Medical School according to IACUC-approved protocols.  Mice 
received 100 µg of codon optimized H1HA DNA vaccine expressing the full-length 
wild type HA protein from A/Texas/04/09 (pH1HA), divided between quadriceps, at 
2 and 4 weeks.  A third boosting immunization was delivered 1-week prior to sacrifice. 
C57BL/6 mice were obtained from Taconic Laboratories. Aim2-/- mice were 
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generated in house by K. Fitzgerald’s group at the University of Massachusetts Medical 
School (UMMS) as previously described [117].  Aim2-/- mice were on a mixed B6/129 
background and therefore B6x129 mice were utilized as controls.  B6.129 (hereafter 
referred to as Aim2+/+) mice were obtained from Jackson Laboratories (Bar Harbor, ME) 
and were bred at UMMS.  IL-1 receptor (Il-1r), IL-18 receptor (Il-18r), and Asc-deficient 
mice were produced in house.  All mice were maintained in the Department of Animal 
Medicine at UMMS according to IACUC-approved protocols.  Mice received 100 µg of 
codon optimized H1HA DNA vaccine expressing the full-length wild type HA 
protein from A/Texas/04/09 (pH1HA), divided between quadriceps, at 2 and 4 weeks.  
A third boosting immunization was delivered 1-week prior to sacrifice. 
Enzyme Linked Immunosorbent Assay (ELISA) 
Transiently expressed H1HA antigen was coated onto 96 well microtiter plates 
(Costar #3369) at ~1 µg/mL in 100 µL of PBS for 1 hour at room temperature. Plates 
were washed 5 times in PBS containing 0.1% Triton-X (EWB) and blocked overnight at 
4° in PBS containing 4% whey and 5% powdered milk.  The following morning, plates 
were washed 5 times in EWB, serially diluted mouse sera, collected at 2 weeks following 
either the secondary DNA immunization, was added to the wells in a volume of 100 µL. 
Plates were washed 5 times in EWB and 100 µL of biotinylanted anti-mouse secondary 
antibody (Vector Labs BA-1000) at 1.5 µg/mL was incubated on the plate for 1 hour at 
room temperature. Plates were washed 5 times with EWB and incubated with 100 µL of 
streptavidin horseradish peroxidase (Vector Labs SA-5004) at 500 ng/mL. Plates were 
washed a final 5 times with EWB and developed for 3 min in 100 µL of a 3,3′5,5′-
tetramethylbenzidine substrate solution (Sigma T3405). The reaction was stopped with 
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addition of 25 µL of 2N H2SO4. Endpoint titers as reported are defined as the last 
dilution of a serially diluted serum sample with greater than twice the background optical 
density of a pre-immune serum sample.  For temporal antibody time courses, pooled 
mouse sera dilutions of 1:100 were generated.  For mouse IgG isotyping, Biotin-
conjugated IgG2b or IgG2c detection antibody (Southern Biotech) was applied at 1.0 
µg/ml. 
NaSCN Displacement 
Transiently expressed H1HA antigen was coated onto 96 well microtiter plates 
(Costar #3369) at 1 µg/mL in 100 µL of PBS for 1 hr at room temperature. Plates were 
washed 5 times in PBS containing 0.1% Triton-X (EWB) and blocked overnight at 4° in 
PBS containing 4% whey and 5% powdered milk.  Mouse sera were then added to the 
plate at a dilution of 1:100 and incubated at room temperature for 1 hour. Plates were 
again washed 5 times in EWB. NaSCN was then added at various (0, 0.5, 1.0, 1.5, 2.0, 
2.5, 3.0 M) concentrations in PBS for 15 min followed by 5 washes in EWB. Bound IgG 
was detected as described above.  Data is reported as the NaSCN concentration required 
to yield an optical density twice that of a pre-immune serum sample. 
Splenocyte preparation 
Spleens were harvested 7 days following the third DNA immunization. Spleens 
were homogenized in complete RPMI media, with 10% heat-inactivated FBS (HyClone, 
Logan, UT), and 1% Penicillin-Streptomycin. Single-cell suspensions were generated by 
homogenization and then draining each spleen through a screen, and washing with media. 
Red blood cells were lysed with Red Blood Cell Lysis Buffer (Sigma Aldrich). Cells 
were washed, counted, and diluted to a final concentration of 1x107 cells/ml. 
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Assays for HA-specific antibody secreting cells  
B-cell ELISpot reagents were obtained from Mabtech (Mariemont, OH).  H1HA-
specific antibody secreting cells in immune mouse splenocytes and bone marrow were 
detected.  MAIPSWU plates, (Millipore, Billerica, MA, USA) were coated with 100 µl (~ 
1.0 µg)/well of transiently expressed H1HA antigen produced from human embryonic 
293T cells and incubated at 4°C overnight.  The plates were washed 5 times with PBS, 
and then blocked by the addition of 200 µl of complete RPMI in each well for 1 hour at 
room temperature. Freshly isolated splenocytes (100 µl/well, 5x105 cells/well) in 
complete RPMI medium with 0.1% β-ME were incubated in triplicate wells for 18 h at 
37°C. The plates were then washed with PBS and incubated with 100 µl of biotinylated 
goat-anti- mouse IgG 1 µg/ml in PBS with 0.5% fetal bovine serum (FBS) at room 
temperature for 2 hours. After additional washes, 100 µl of HRP-conjugated Streptavidin 
complex diluted at 1:1000 in PBS with 0.5% FBS was added to each well and incubated 
at room temperature for 1 hour, then spots were developed by a 3 minute color reaction 
using 100 µL of a 3,3′5,5′-tetramethylbenzidine substrate solution. The number of H1HA 
specific ASCs was counted and calculated. 
T Cell ELISpot 
ELISpot reagents (IFNγ) were obtained from Mabtech (Mariemont, OH).  
ELISpots were performed according to manufacturer’s instructions. Pre-coated MSIP 
PVDF-plates (Millipore, Billerica, MA) were seeded with splenocytes from immunized 
mice (prepared as above) at a 2.5x105 cells/well.  Positive controls were stimulated with 
20 ng/ml phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO) and 
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500 ng/ml ionomycin (Sigma-Aldrich).  The H1HA relevant peptide used was a CD8+ 
cell-restricted HA peptide (IYSTVASSL).  Antigen-specific stimulation was performed 
with a concentration of 15 µg/ml.  Mock stimulated wells received media only. Plates 
were incubated 18-20 hr at 37o C.  Plates were developed according to manufacturers 
instructions.  Positive spots were visualized on a CTL Imager and counting was 
performed with Immunospot software (Cellular Technology Ltd., Shaker Heights, OH) 
Serum Cytokine Levels 
Type I IFN study cytokine levels were quantified in sera collected from individual 
mice prior to immunization at week 0 and 6 hours post primary DNA using the Mouse 
Th1/Th2/Th17 CBA kit (BD Biosciences, Franklin Lakes, NJ) according to manufacturer’s 
instructions. The panel of cytokines included: IFN-γ, IL-2, IL-4, IL-6, TNF, IL-10, and 
IL-17. After collection, serum samples were stored at -80o C until the conclusion of the 
study, and all serum samples from each time point of interest were run in a single CBA 
experiment. Prior to assay, serum samples were diluted 1:2 in sample diluent. Samples 
were read on a LSRII flow cytometer and analyzed with FCAP Array Software version 
3.0 (BD Biosciences). 
Inflammasome study cytokine and chemokine levels were quantified in serum 
collected from individual mice prior to immunization at week 0, and 6 hours post primary 
DNA using a custom Bio-Plex cytokine assay (Bio-Rad, Hercules, CA) according to 
manufacturer’s instructions. The panel of cytokines included: IFNγ, IL-1β, IL-2, IL-4, IL-
6, Eotaxin, G-CSF, KC, MIP-1α, MIP-1β, MCP-1, and RANTES. After collection, serum 
samples were stored at -80o C until the conclusion of the study, and all serum samples 
from each time point of interest were run in a single Luminex experiment. Prior to assay, 
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serum samples were diluted 1:4 in sample diluent. Samples were read on a Bio-Plex 200 
system with Bio-Plex Manager software (Bio-Rad). 
Quantitative Real Time-Polymerase Chain Reaction 
Mice were shaved and immunized with 100 µg H1-TX04-09.tPA DNA vaccine 
plasmid intramuscularly injected into the hind quad muscle.  Punch biopsies were 
harvested from the site of immunization at 6 hours, 12 hours, and 24 hours post 
immunization and snap frozen.  RNA was isolated from tissues biopsies using TRIzol 
Reagent (Life Technologies #15596-026), and cDNA was generated using the Bio Rad 
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA).  cDNA was then used for RT-PCR 
reactions on a Bio-Rad CFX-96 cycler.  Primers sequences are available upon request. 
In Vivo Caspase-1 activation 
 Aim2+/+ and Aim2-/- mice were shaved and immunized with 100 µg H1-TX04-
09.tPA DNA vaccine plasmid intramuscularly injected into the hind quad muscle.  Punch 
biopsies were harvested from the site of immunization at 6 hours, 12 hours, and 24 hours 
post immunization and snap frozen.  Cryopreserved tissue sections were generated and 
adhered to glass slides.  Samples were then stained with a caspase-1 FAM/FLICA kit 
according to manufacturer’s instructions (ImmunoChemistry Technologies, Bloomington, 
MN).  Stained slides were visualized on a confocal microscope. Sixteen independent 
fields were analyzed for fluorescence. 
Gene Induction Analysis 
 C57BL/6 mice were shaved and immunized with 100 µg H1-TX04-09.tPA DNA 
vaccine plasmid intramuscularly injected into the hind quad muscle.  Punch biopsies were 
harvested from the site of immunization at 6 hours, 12 hours, and 24 hours post 
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immunization and snap frozen.  RNA was isolated from tissue biopsies using TRIzol 
Reagent (Life Technologies).  We analyzed gene expression using the Nanostring 
nCounter Analysis system (Nanostring Technologies).  Each reaction contained 100 ng 
RNA in a 5 µl aliquot, plus reporter and capture probes.  We also included 6 pairs of 
positive control and 8 pairs of negative control probes.  Gene induction analysis and 
normalization was conducted using nSolver Analysis Software v1.1.  Raw counts were 
normalized to naïve mice using 3 reference genes: Gapdh, Gusb, and Hprt1.  
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Aluminum Adjuvant Study Materials and Methods 
Mice 
Aim2-/- mice were from K. Fitzgerald (UMass Medical School) and were 
generated as previously described [117].  Aim2-/- mice were on a mixed B6/129 
background and therefore B6x129 mice were utilized as controls.  B6.129 mice (hereafter 
referred to as Aim2+/+) were obtained from Jackson Laboratories (Bar Harbor, ME) and 
were bred at UMass Medical School. All mice were maintained in the Department of 
Animal Medicine at UMass Medical School according to IACUC-approved protocols.  
Mice received either 1.5 ug Aventis Pasteur Fluzone 2004-2005 trivalent inactivated 
vaccine (TIV) alone or absorbed onto 65 ug Alhydrogel®, divided between quadriceps, at 
2 and 4 weeks.  A third boosting immunization was delivered 1-week prior to sacrifice. 
 Cell Culture and Stimulation and IL-1β Measurement 
Aim2+/+ and Aim2-/- immortalized BMDM were a gift from Katherine Fitzgerald 
(UMass Medical School, MA).  Cells were first primed with 200 ng/ml LPS (Sigma 
Aldrich) for 4-5 h prior to treatment with appropriate stimulus. All media was removed 
from the cells, and the appropriate stimulus was added.  Poly (dA:dT) (Sigma Aldrich) 
was transfected using Lipofectamine 2000 at a concentration of 1.5 µg/well.  ATP was 
added at a concentration of 1.25 µg/ml.  Alhydrogel® was added to cultures at a 
concentration of 100 µg/ml. Cultures were incubated 16-18 hours at 37 o C, and 
supernatants were harvested.  Cell culture supernatants were assayed for IL-1β (BD 
Biosciences, Franklin Lakes, NJ) by ELISA. 
Enzyme Linked Immunosorbent Assay (ELISA) 
109
Transiently expressed New Caledonia H1HA antigen was coated onto microtiter 
plates (Costar #3369) at ~1 µg/mL in 100 µL of PBS for 1 hour at room temperature and 
assayed as previously described [142].  NaSCN displacement was performed at a serum 
dilution of 1:100.  After washing of serum samples, NaSCN was added at various (0, 0.5, 
1.0, 1.5, 2.0, 2.5, 3.0 M) concentrations in PBS for 15 min followed by 5 washes in 
EWB.  The assay was then completed as above. 
Quantification of HA specific T and B Cells 
Splenocyte T and B cell ELISPOT reagents were obtained from Mabtech 
(Mariemont, OH).  H1HA specific T cells were quantified per manufactures instructions. 
Positive controls were stimulated with 20 ng/ml PMA (Sigma-Aldrich, St. Louis, MO) 
and 500 ng/ml ionomycin (Sigma-Aldrich).  The H1HA relevant peptide used was a 
CD8+ cell-restricted HA peptide (IYSTVASSL). New Caledonia H1HA-specific 
antibody secreting cells were detected by coating of MAIPSWU (Millipore, Billerica, 
MA, USA) plates with the transiently expressed H1HA antigen utilized for ELISA (~1.0 
µg/well).  Positive spots were visualized on a CTL Imager and counting was performed 
with Immunospot software (Cellular Technology Ltd., Shaker Heights, OH) 
Quantitative Real Time-Polymerase Chain Reaction 
Aim2+/+ and Aim2-/- mice were shaved and immunized with 1.5 ug Aventis Pasteur 
Fluzone 2004-2005 trivalent inactivated vaccine (TIV) onto 65 ug alum via intramuscular 
injection into the hind quad muscle.  Punch biopsies were harvested from the site of 
immunization at 6 hours, 12 hours, and 24 hours post immunization and snap frozen.  
RNA was isolated from tissues biopsies using TRIzol Reagent (Life Technologies 
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#15596-026), and cDNA was generated using the Bio Rad iScript cDNA synthesis kit 
(Bio-Rad, Hercules, CA).  cDNA was then used for rt-PCR reactions on a Bio-Rad CFX-
96 cycler.  Primers sequences are available upon request. 
Reagents 
ATP, LPS, and poly(dA-dT) were from Sigma-Aldrich. 
Statistical analysis 
All data is presented as the mean of individual mice +/- standard error of the mean 
(SEM). Statistical analysis was performed using a Student’s t test, a one-way ANOVA 
followed by a Tukey post-test, or a two-way ANOVA followed by a Bonferonni post-
test.  
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Chapter VI 
Final Comments and Conclusions 
The future of DNA vaccination is bright.  Advances in plasmid design, and 
vaccine delivery systems have overcome initial setbacks related to low immunogenicity 
in humans.  DNA vaccination has proven successful even in the face of notoriously 
difficult pathogens such as HIV and pandemic influenza.  The utility of DNA vaccination 
can be further seen in the heterologous prime-boost strategy, wherein DNA vaccines 
boost the adaptive immune response generated by more conventional protein-based 
vaccine modalities.  DNA priming of hosts yields higher level cellular and humoral 
immunity than two doses of protein alone.  The mechanism behind the increased DNA 
vaccine-induced adaptive immunity is not completely understood, but it is imperative 
researchers begin to understand the extracellular and intracellular processes governing 
DNA vaccination in order to design safer, more effective vaccines. 
 Many questions remain about the nature of DNA vaccines and their interactions 
with the immune system.  The immunostimulatory nature of DNA is well known. It is 
believed that the bacterial plasmid backbone itself functions as an inherent adjuvant in 
DNA vaccination; however, the beneficial effect of vaccine plasmid immunization has 
not been truly addressed.  Clarification of the ability of the empty vaccine plasmid to 
boost both innate and adaptive immune responses by co-immunization with a protein 
based vaccine such as the TIV utilized here would help to define the plasmid’s 
immunostimulatory nature.  Such a study may prove that DNA vaccine plasmids 
themselves, independent of plasmid encoded antigen, are immunogenic and are at least 
partially responsible for the increase in adaptive immune responses seen in DNA prime-
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protein boost patients.  This study is crucial gaining a more complete understanding of 
the underlying mechanism of DNA vaccination. 
In Chapter II, I explored the non-canonical IFN-αβ inducing STING pathway. 
Evidence suggests that cytosolic DNA sensing pathways regulate DNA vaccine 
immunogenicity [81, 95].  Currently, only the dsDNA-induced, non-canonical 
STING/TBK1/IFN-αβ signaling cascade has been shown to mediate the induction of 
adaptive immune responses by DNA vaccination.  Though several candidates exist, the 
cytosolic DNA sensor has yet to be identified.  Unfortunately, my attempt to identify the 
sole upstream regulator of STING-dependent IFN-αβ production was unsuccessful.  As 
cGAS is required for IFN-αβ production in response to both DNA virus and bacterial 
infection [85, 86, 91, 147], I hypothesized that it would also be necessary for DNA 
vaccine immunogenicity.  However, despite its importance in pathogen infection, the 
induction of adaptive immune responses following DNA vaccination appears to be cGAS 
independent.  While cGas-/- mice did exhibit an initial impairment in IFN-αβ production 
immediately following immunization, wild-type levels were reached within 12 hours. 
One possible interpretation of these findings is that cGAS is the dominant cytosolic DNA 
sensor in the early stages of DNA vaccination, but that at least one other cytosolic sensor 
is able to compensate for cGAS deletion, albeit in a delayed manner.  The incongruity 
between infection and vaccination studies is most likely due to the fact that DNA 
vaccines are non-replicative and incapable of causing disease.  Where a delay in innate 
immune signaling may yield high viral or bacterial loads resulting in illness or death, 
DNA vaccines pose no such risk.  Therefore, the delay in IFN-αβ induction by redundant 
sensors does not appear to have a detrimental effect on the overall immune response.   
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The question still remains of what cytosolic DNA sensors are required for DNA 
vaccine immunogenicity.  The most obvious approach to confirming the hypothesis that 
multiple DNA sensors activate STING following DNA immunization is to cross cGas-/- 
mice with other candidate receptors, although this may prove difficult, as multiple IFN-
αβ inducing sensors may act in parallel and in different cell types.  An alternative 
possibility is that cGAMP, the endogenous activator of STING, is produced by a second 
sensor, independent of cGAS.  It would be informative to quantify cGAMP levels in 
cGas-/- mice at the site of injection by either rt-PCR or Nanostring to address this 
possibility.  Similarly, it is possible that a molecule sharing a similar conformational 
structure to the cyclic dinucleotide cGAMP may bind to STING and drive IFN-α/β 
production.  cGAS belongs to a family of cytosolic nucleic acid sensors that also includes 
the dsRNA sensing 2ʹ–5ʹ-oligoadenylate synthase (OAS) proteins.  OAS proteins produce 
2ʹ–5ʹ-oligoadenylate in response to both cellular and viral RNA, although structural 
analysis of these receptors suggests that they do not readily bind to DNA [90, 180, 181].  
In vitro STING pull down experiments in DNA vaccine transfected cGas-/- cells may be 
useful in identifying any bound cyclic dinucleotides.  In vivo analysis is more 
complicated as it is necessary to generate cGAS/OAS1 or cGAMP/2ʹ–5ʹ-oligoadenylate 
double knockout mice to confirm that OAS proteins do not have a role in STING-
dependent DNA vaccine immunogenicity. 
With regards to the necessity of the IRF3 and IRF7 transcription factors in 
inducing adaptive immune responses, several questions still remain.  Perhaps the most 
pressing question is the lack of requirement for IRF3 in DNA vaccination.  This suggests 
that IRF3 is not required for sustained IFN-α/β production following DNA vaccination.  
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Honda et al. have proposed that IRF3 contributes little to immune responses in the 
absence of IRF7 because interaction with IRF7 is required for IRF3 to function 
completely [79].  Furthermore, it has been established that that IRF7 is crucial for the 
cytosolic pathway of IFN-αβ induction [79, 182].  Therefore, it is necessary to quantify 
IFN-α/β levels in Irf3-/- mice using the punch biopsy rt-PCR assay.  Unfortunately, a lack 
of available Irf3-/- mice precluded these assays from being performed.  Conversely, it is 
possible that IFN-β is dispensable for DNA vaccination and that the primary interferon 
signal is provided by IFN-α.  The requirement for either IFN-α or IFN-β in DNA vaccine 
immunogenicity can be confirmed by treating Irf7-/- mice with recombinant murine IFN-α 
and/or IFN-β protein prior to DNA immunization in an attempt to rescue the innate and 
adaptive immune responses generated.   
In addition to the anti-viral STING/TBK1/IRF7 pathway, I also investigated the 
previously unexplored pro-inflammatory pathway in Chapter III.  Both the humoral and 
cellular antigen-specific adaptive responses were significantly reduced in Aim2-/- mice in 
an IL-1β/IL-18 independent manner after DNA vaccination.  Surprisingly, Aim2-/- mice 
also exhibited significantly lower levels of IFN-α/β at the site of injection.  I therefore 
propose that the defect in IFN-α/β induction is related to impaired pyroptotic cell death 
by DNA plasmid transfected cells.  My current hypothesis is that genomic DNA released 
into the extracellular milieu by pyroptotic cell death triggers the activation of the 
STING/TBK1 pathway in bystander cells via cGAS or another of the putative cytosolic 
DNA sensors.  However, other possibilities do exist. The initial reports on STING 
activity demonstrated that Sting-deficient mice are susceptible to infection with RNA 
viruses such as vesicular stomatitis virus (VSV) or Sendai virus [80].  This suggests that 
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RNA is capable of inducing a STING-dependent IFN-α/β response through a pathway 
that has yet to be thoroughly investigated.  However, as the deletion of MAVS does not 
limit DNA vaccine immunogenicity, STING signaling in this manner would function 
through a previously undescribed mechanism.  Furthermore, the release of other 
intracellular DAMPs such as high mobility group box 1 protein (HMGB1) or heat shock 
proteins have been shown to induce IFN-α/β production via multiple TLR pathways 
[183], but the ability of these DAMPs to serve as a secondary signal for DNA vaccine 
immunogenicity is unlikely, as TLR deletion has no effect on the adaptive immune 
responses generated [95].   
Notably, the role of AIM2-dependent IFN-α/β production in regulating the 
adaptive immune response still remains to be definitively addressed.  It is conceivable 
that while Aim2-/- mice exhibit impaired IFN-α/β production locally, this is not the only 
mechanism limiting the development of antigen-specific immune responses.  One 
experiment to confirm my hypothesis is the injection of recombinant IFN-α/β into Aim2-/- 
mice following DNA vaccination.  If my hypothesis is correct, introduction of exogenous 
IFN-α/β into the system will rescue the impaired adaptive immune responses seen in 
Aim2-/- mice.  It would be particularly interesting if a partial rescue of the immune 
phenotype following recombinant IFN-α/β injection were seen.  This would suggest that 
at least one other factor in addition to IFN-α/β is limiting the adaptive response. 
Importantly, it is also necessary for subsequent studies to focus on the necessity of 
caspase-1 directly.  While the data presented here proves that ASC is required for optimal 
DNA vaccine immunogenicity, it does not eliminate the possibility of other caspases 
playing a role in DNA vaccine immunogenicity.  Recent evidence has shown that cells 
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deficient in caspase-1 may revert to AIM2/ASC/caspase-8 dependent cellular apoptosis 
upon cytosolic DNA sensing [184].  This leaves open the possibility that AIM2-
dependent apoptotic cell death may also influence the adaptive immune responses 
generated following DNA vaccination.  Likewise, caspase-11 has been reported to induce 
pyroptotic cell death independently of caspase-1, suggesting at least one alternative 
pathway for release of pro-inflammatory signals [185, 186]. 
The data presented in this thesis represents a series of novel findings that further 
elucidates the role of innate immunity in influencing the adaptive immune response to 
DNA vaccination. I have shown that both the anti-viral IFN-α/β and the pro-
inflammatory pathways are required for optimal DNA vaccine immunogenicity.  One of 
the goals of this thesis was to identify a common innate immune signaling pathway 
involved in DNA vaccine immunogenicity.  I propose that the pro-inflammatory and anti-
viral pathways are linked via DAMP release from pyroptotic cells.  These DAMPs, most 
likely genomic DNA, are detected by nearby bystander cells, and amplify the IFN-α/β 
response, thereby boosting both the humoral and CMI responses (Figure 6.1).  
Collectively, these findings provide a firm basis for understanding the relationship 
between innate immune signals and adaptive immunity, allowing for the design of more 
effective DNA vaccines. For instance, it may be possible to alter the vaccine plasmid 
backbone so as to include immunostimulatory motifs specific for particular DNA 
receptors.  Likewise, knowledge of the transcription factors involved in regulating the 
immune response, such as IRF7, allows for the encoding of highly immunogenic genes 
within the vaccine plasmid, providing an additional adjuvant effect.  It would therefore be 
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possible to tailor the vaccine plasmid to produce those conditions that are optimal for the 
desired immune response or a given pathogen. 
 As a final note, I began preliminary work drawing on recent literature exploring 
roles for inflammasome signaling in aluminum salt adjuvants. Multiple reports have 
suggested that alum adjuvanticity is dependent on the NLRP3 inflammasome [170-172]. 
However, several other groups have presented contrasting data demonstrating that 
NLRP3 signaling is dispensable for alum’s adjuvant effects in vivo.  More recent reports 
have argued that cytotoxic release of host DNA mediates the adjuvant activity of alum 
via a TBK1-dependent IFN-α/β pathway [128, 129, 177].  As such, I hypothesized that 
the AIM2-dependent pyroptotic release of genomic DNA is required for alum 
adjuvanticity.  Alum + TIV immunized Aim2-/- mice exhibited impaired humoral immune 
responses compared to Aim2+/+ mice.  This impairment seems to be mediated in part by 
decreased IFN-αβ at the site of immunization.  I propose that alum adjuvant signals 
through AIM2 in a manner analogous to the one proposed for DNA vaccination, whereby 
pyroptotic cell death enhances both anti-viral and pro-inflammatory signaling, most 
likely via the STING/TBK1 pathway.  Therefore, it would be prudent to conduct the 
studies suggested above for AIM2 and DNA vaccination within this model as well.  Of 
particular importance are those involving the release of pro-inflammatory signaling and 
IFN-αβ production.  Of note, a key control missing from these studies is the use of a type 
I IFN-independent adjuvant such as the squalene based MF59 to confirm the requirement 
for AIM2-dependent IFN-αβ in alum adjuvanticity.  At the very least, the results obtained 
in Aim2-/- mice may partially explain the discrepancies seen in NLRP3 deletion studies, as 
AIM2 allows for the continued induction of IL-1β.  While these experiments were 
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preliminary in nature, they lay the groundwork for future study and establish a previously 
unreported role for AIM2 in alum adjuvanticity. 
 In closing, as most successful vaccines and adjuvants stimulate innate immune 
pathways, my data would suggest that the pathways outlined herein may play a role in 
traditional vaccine modalities as well.  While the pro-inflammatory and anti-viral 
pathways are generally regarded as divergent, the work presented here illustrates how 
complex their interactions truly are, and demonstrates that both pathways play essential 
roles in shaping the adaptive immune responses produced by vaccination. 
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Figure 6.1: Proposed model for innate immune recognition of DNA vaccines. 
Three distinct pathways detect DNA vaccine plasmid.  (A) Cytosolic vaccine plasmid 
engages and activates the AIM2 inflammasome, resulting in binding to the adaptor ASC.  
ASC mediates caspase-1-dependent pro-IL-1β/pro-IL-18 cleavage and secretion of their 
bioactive forms.  Caspase-1 activation also results in pyroptotic cell death and the release 
of pro-inflammatory DAMPs, including genomic DNA.  Released genomic DNA may 
then be detected by surrounding bystander cells, inducing type I IFN production through 
the STING/TBK1/IFN-αβ pathway.  (B) An unknown cytosolic DNA sensor detects 
DNA vaccine plasmid, activating the non-canonical STING/TBK1/IFN-αβ inducing 
pathway.  STING/TBK1 activation results in IRF7 phosphorylation and dimerization, 
generating high levels of IFN-αβ.  (C) Extracellular CpG-rich DNA plasmid is 
transported to TLR9-positive endosomal compartments.  TLR9 recognition of DNA 
plasmid signals via the MyD88/IKKβ/IRF7 pathway to induce IFN-αβ production.  Red 
arrows represent pathways mediating DNA vaccine immunogenicity. 
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